drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00065 | DB00075 | 581 | 541 | [
"DDInter923",
"DDInter1250"
] | Infliximab | Muromonab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). | Major | 2 | [
[
[
581,
25,
541
]
],
[
[
581,
23,
1193
],
[
1193,
62,
541
]
],
[
[
581,
25,
270
],
[
270,
63,
541
]
],
[
[
581,
24,
58
],
[
58,
63,
541
]
],
[
[
581,
64,
1184
],
[
1184,
24,
541
]
],
[
[
581,
25,
1066
],
[
1066,
64,
541
]
],
[
[
581,
64,
1057
],
[
1057,
25,
541
]
],
[
[
581,
23,
1193
],
[
1193,
23,
270
],
[
270,
63,
541
]
],
[
[
581,
25,
270
],
[
270,
62,
1193
],
[
1193,
62,
541
]
],
[
[
581,
25,
287
],
[
287,
63,
270
],
[
270,
63,
541
]
]
] | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Muromonab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Muromonab"
]
]
] | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Muromonab
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Muromonab
Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Muromonab
Infliximab may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Muromonab |
DB00618 | DB11248 | 1,572 | 1,193 | [
"DDInter498",
"DDInter1965"
] | Demeclocycline | Zinc gluconate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia , , , . Studies show that zinc may be better absorbed in humans in the gluconate form , , however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrheal episodes for up to 12 weeks . More information about Zinc (in its natural form) is available at . | Moderate | 1 | [
[
[
1572,
24,
1193
]
],
[
[
1572,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
1572,
24,
260
],
[
260,
62,
1193
]
],
[
[
1572,
40,
1620
],
[
1620,
24,
1193
]
],
[
[
1572,
1,
1669
],
[
1669,
24,
1193
]
],
[
[
1572,
24,
1096
],
[
1096,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
1572,
24,
1596
],
[
1596,
62,
1096
],
[
1096,
23,
1193
]
],
[
[
1572,
24,
955
],
[
955,
1,
1096
],
[
1096,
23,
1193
]
],
[
[
1572,
40,
1620
],
[
1620,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
1572,
1,
1669
],
[
1669,
24,
1096
],
[
1096,
23,
1193
]
]
] | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
],
[
"Ferrous sulfate anhydrous",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
]
] | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate |
DB00092 | DB01097 | 58 | 1,377 | [
"DDInter40",
"DDInter1033"
] | Alefacept | Leflunomide | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
58,
25,
1377
]
],
[
[
58,
23,
1461
],
[
1461,
23,
1377
]
],
[
[
58,
23,
1193
],
[
1193,
62,
1377
]
],
[
[
58,
24,
949
],
[
949,
63,
1377
]
],
[
[
58,
24,
126
],
[
126,
24,
1377
]
],
[
[
58,
24,
1491
],
[
1491,
64,
1377
]
],
[
[
58,
24,
1001
],
[
1001,
25,
1377
]
],
[
[
58,
25,
779
],
[
779,
64,
1377
]
],
[
[
58,
63,
1184
],
[
1184,
25,
1377
]
],
[
[
58,
25,
1066
],
[
1066,
25,
1377
]
]
] | [
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide
Alefacept may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Leflunomide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Leflunomide
Alefacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Leflunomide |
DB00397 | DB00472 | 1,466 | 758 | [
"DDInter1458",
"DDInter758"
] | Phenylpropanolamine | Fluoxetine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Major | 2 | [
[
[
1466,
25,
758
]
],
[
[
1466,
63,
847
],
[
847,
1,
758
]
],
[
[
1466,
25,
109
],
[
109,
40,
758
]
],
[
[
1466,
1,
838
],
[
838,
1,
758
]
],
[
[
1466,
6,
7390
],
[
7390,
45,
758
]
],
[
[
1466,
18,
10375
],
[
10375,
57,
758
]
],
[
[
1466,
21,
28929
],
[
28929,
60,
758
]
],
[
[
1466,
24,
542
],
[
542,
23,
758
]
],
[
[
1466,
63,
1152
],
[
1152,
23,
758
]
],
[
[
1466,
24,
1148
],
[
1148,
63,
758
]
]
] | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} (Compound) resembles {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound)",
"Isoxsuprine"
],
[
"Isoxsuprine",
"{u} (Compound) resembles {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluoxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
]
] | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Fluoxetine (Compound)
Phenylpropanolamine may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound)
Phenylpropanolamine (Compound) resembles Isoxsuprine (Compound) and Isoxsuprine (Compound) resembles Fluoxetine (Compound)
Phenylpropanolamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Fluoxetine (Compound)
Phenylpropanolamine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Fluoxetine (Compound)
Phenylpropanolamine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Fluoxetine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Fluoxetine
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Fluoxetine
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine |
DB00086 | DB01240 | 1,167 | 885 | [
"DDInter1712",
"DDInter657"
] | Streptokinase | Epoprostenol | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1167,
24,
885
]
],
[
[
1167,
24,
1061
],
[
1061,
1,
885
]
],
[
[
1167,
23,
539
],
[
539,
62,
885
]
],
[
[
1167,
24,
1512
],
[
1512,
24,
885
]
],
[
[
1167,
64,
1432
],
[
1432,
24,
885
]
],
[
[
1167,
63,
1595
],
[
1595,
24,
885
]
],
[
[
1167,
24,
972
],
[
972,
63,
885
]
],
[
[
1167,
25,
126
],
[
126,
24,
885
]
],
[
[
1167,
25,
1046
],
[
1046,
63,
885
]
],
[
[
1167,
25,
1618
],
[
1618,
64,
885
]
]
] | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
]
]
] | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Epoprostenol
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Streptokinase may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Epoprostenol |
DB00619 | DB12457 | 1,419 | 1,180 | [
"DDInter909",
"DDInter1598"
] | Imatinib | Rimegepant | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists that possessed oral bioavailability until the approval of [atogepant] in 2021. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.[A189330,A189207] | Moderate | 1 | [
[
[
1419,
24,
1180
]
],
[
[
1419,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
1419,
24,
1501
],
[
1501,
63,
1180
]
],
[
[
1419,
25,
927
],
[
927,
24,
1180
]
],
[
[
1419,
35,
1468
],
[
1468,
24,
1180
]
],
[
[
1419,
63,
883
],
[
883,
24,
1180
]
],
[
[
1419,
24,
1220
],
[
1220,
25,
1180
]
],
[
[
1419,
25,
129
],
[
129,
25,
1180
]
],
[
[
1419,
24,
1619
],
[
1619,
24,
1501
],
[
1501,
63,
1180
]
],
[
[
1419,
24,
1501
],
[
1501,
63,
1619
],
[
1619,
24,
1180
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
]
] | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Rimegepant
Imatinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Rimegepant
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant |
DB00261 | DB00963 | 702 | 1,263 | [
"DDInter93",
"DDInter241"
] | Anagrelide | Bromfenac | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Moderate | 1 | [
[
[
702,
24,
1263
]
],
[
[
702,
24,
935
],
[
935,
40,
1263
]
],
[
[
702,
24,
1512
],
[
1512,
24,
1263
]
],
[
[
702,
18,
9205
],
[
9205,
57,
1263
]
],
[
[
702,
21,
28688
],
[
28688,
60,
1263
]
],
[
[
702,
24,
752
],
[
752,
23,
1263
]
],
[
[
702,
24,
578
],
[
578,
63,
1263
]
],
[
[
702,
63,
1018
],
[
1018,
24,
1263
]
],
[
[
702,
25,
877
],
[
877,
63,
1263
]
],
[
[
702,
64,
273
],
[
273,
24,
1263
]
]
] | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"IFRD2"
],
[
"IFRD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Epistaxis"
],
[
"Epistaxis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
],
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
]
] | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Bromfenac (Compound)
Anagrelide (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Bromfenac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bromfenac
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Anagrelide may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Anagrelide may lead to a major life threatening interaction when taken with Tositumomab and Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac |
DB00341 | DB00372 | 1,242 | 999 | [
"DDInter343",
"DDInter1793"
] | Cetirizine | Thiethylperazine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
1242,
24,
999
]
],
[
[
1242,
63,
784
],
[
784,
24,
999
]
],
[
[
1242,
24,
1614
],
[
1614,
63,
999
]
],
[
[
1242,
24,
695
],
[
695,
24,
999
]
],
[
[
1242,
35,
252
],
[
252,
63,
999
]
],
[
[
1242,
74,
701
],
[
701,
24,
999
]
],
[
[
1242,
24,
684
],
[
684,
64,
999
]
],
[
[
1242,
63,
534
],
[
534,
25,
999
]
],
[
[
1242,
63,
784
],
[
784,
24,
1614
],
[
1614,
63,
999
]
],
[
[
1242,
24,
1614
],
[
1614,
24,
17
],
[
17,
63,
999
]
]
] | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
]
] | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin and Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine (Compound) resembles Hydroxyzine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin and Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine |
DB00209 | DB01192 | 352 | 560 | [
"DDInter1886",
"DDInter1372"
] | Trospium | Oxymorphone | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. | Moderate | 1 | [
[
[
352,
24,
560
]
],
[
[
352,
24,
828
],
[
828,
1,
560
]
],
[
[
352,
6,
12523
],
[
12523,
45,
560
]
],
[
[
352,
21,
28817
],
[
28817,
60,
560
]
],
[
[
352,
24,
1123
],
[
1123,
24,
560
]
],
[
[
352,
24,
820
],
[
820,
63,
560
]
],
[
[
352,
35,
1192
],
[
1192,
24,
560
]
],
[
[
352,
24,
475
],
[
475,
36,
560
]
],
[
[
352,
24,
828
],
[
828,
40,
81
],
[
81,
1,
560
]
],
[
[
352,
24,
421
],
[
421,
1,
81
],
[
81,
1,
560
]
]
] | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrocodeine"
],
[
"Dihydrocodeine",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Dihydrocodeine"
],
[
"Dihydrocodeine",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
]
]
] | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxymorphone (Compound)
Trospium (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Oxymorphone (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) resembles Oxymorphone (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxymorphone
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Dihydrocodeine (Compound) and Dihydrocodeine (Compound) resembles Oxymorphone (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Dihydrocodeine (Compound) and Dihydrocodeine (Compound) resembles Oxymorphone (Compound) |
DB00242 | DB06688 | 1,064 | 1,430 | [
"DDInter392",
"DDInter1677"
] | Cladribine | Sipuleucel-T | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. | Major | 2 | [
[
[
1064,
25,
1430
]
],
[
[
1064,
25,
175
],
[
175,
24,
1430
]
],
[
[
1064,
24,
869
],
[
869,
24,
1430
]
],
[
[
1064,
25,
676
],
[
676,
63,
1430
]
],
[
[
1064,
64,
491
],
[
491,
24,
1430
]
],
[
[
1064,
36,
1488
],
[
1488,
24,
1430
]
],
[
[
1064,
37,
1224
],
[
1224,
24,
1430
]
],
[
[
1064,
25,
175
],
[
175,
25,
676
],
[
676,
63,
1430
]
],
[
[
1064,
25,
51
],
[
51,
24,
869
],
[
869,
24,
1430
]
],
[
[
1064,
24,
869
],
[
869,
63,
51
],
[
51,
24,
1430
]
]
] | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
]
] | Cladribine may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may lead to a major life threatening interaction when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine (Compound) resembles Fludarabine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cladribine may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T |
DB01172 | DB09156 | 416 | 777 | [
"DDInter1004",
"DDInter964"
] | Kanamycin | Iopromide | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can cause several serious adverse effects, including cardiac events, thromboembolism, hypersensitivity reaction, and even death if administered intrathecally inadvertently, it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events. Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and orthography.[L46906,L46911] | Major | 2 | [
[
[
416,
25,
777
]
],
[
[
416,
64,
1028
],
[
1028,
24,
777
]
],
[
[
416,
23,
699
],
[
699,
24,
777
]
],
[
[
416,
24,
242
],
[
242,
63,
777
]
],
[
[
416,
63,
372
],
[
372,
25,
777
]
],
[
[
416,
24,
1381
],
[
1381,
64,
777
]
],
[
[
416,
64,
1441
],
[
1441,
25,
777
]
],
[
[
416,
24,
712
],
[
712,
25,
777
]
],
[
[
416,
74,
1132
],
[
1132,
25,
777
]
],
[
[
416,
25,
1329
],
[
1329,
25,
777
]
]
] | [
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
],
[
"Plazomicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
],
[
"Gallium nitrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
]
] | Kanamycin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Kanamycin may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iopromide
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may lead to a major life threatening interaction when taken with Iopromide
Kanamycin may lead to a major life threatening interaction when taken with Bacitracin and Bacitracin may lead to a major life threatening interaction when taken with Iopromide
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Iopromide
Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Iopromide
Kanamycin may lead to a major life threatening interaction when taken with Gallium nitrate and Gallium nitrate may lead to a major life threatening interaction when taken with Iopromide |
DB06691 | DB06702 | 849 | 573 | [
"DDInter1155",
"DDInter731"
] | Mepyramine | Fesoterodine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
849,
24,
573
]
],
[
[
849,
63,
211
],
[
211,
1,
573
]
],
[
[
849,
6,
12523
],
[
12523,
45,
573
]
],
[
[
849,
74,
100
],
[
100,
24,
573
]
],
[
[
849,
63,
1442
],
[
1442,
24,
573
]
],
[
[
849,
24,
1429
],
[
1429,
63,
573
]
],
[
[
849,
63,
211
],
[
211,
1,
494
],
[
494,
1,
573
]
],
[
[
849,
63,
494
],
[
494,
40,
211
],
[
211,
1,
573
]
],
[
[
849,
6,
12523
],
[
12523,
45,
211
],
[
211,
1,
573
]
],
[
[
849,
74,
100
],
[
100,
24,
211
],
[
211,
1,
573
]
]
] | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
]
] | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Mepyramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Disopyramide (Compound) and Disopyramide (Compound) resembles Fesoterodine (Compound)
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Tolterodine (Compound) and Tolterodine (Compound) resembles Fesoterodine (Compound)
Mepyramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tolterodine (Compound) and Tolterodine (Compound) resembles Fesoterodine (Compound)
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound) |
DB01037 | DB08912 | 1,161 | 1,040 | [
"DDInter1653",
"DDInter462"
] | Selegiline | Dabrafenib | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
1161,
24,
1040
]
],
[
[
1161,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1161,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1161,
63,
245
],
[
245,
24,
1040
]
],
[
[
1161,
25,
222
],
[
222,
24,
1040
]
],
[
[
1161,
24,
1296
],
[
1296,
63,
1040
]
],
[
[
1161,
24,
959
],
[
959,
24,
1040
]
],
[
[
1161,
24,
1017
],
[
1017,
64,
1040
]
],
[
[
1161,
6,
4973
],
[
4973,
17,
2097
],
[
2097,
46,
1040
]
],
[
[
1161,
6,
3486
],
[
3486,
45,
168
],
[
168,
23,
1040
]
]
] | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) regulates {v} (Gene)",
"ERBB2"
],
[
"ERBB2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
]
] | Selegiline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Selegiline (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Selegiline may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Dabrafenib
Selegiline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Selegiline (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib |
DB00708 | DB04843 | 1,454 | 1,511 | [
"DDInter1718",
"DDInter1149"
] | Sufentanil | Mepenzolate | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. | Moderate | 1 | [
[
[
1454,
24,
1511
]
],
[
[
1454,
24,
537
],
[
537,
24,
1511
]
],
[
[
1454,
63,
352
],
[
352,
24,
1511
]
],
[
[
1454,
24,
649
],
[
649,
1,
1511
]
],
[
[
1454,
21,
28722
],
[
28722,
60,
1511
]
],
[
[
1454,
24,
849
],
[
849,
63,
1511
]
],
[
[
1454,
1,
1322
],
[
1322,
24,
1511
]
],
[
[
1454,
63,
701
],
[
701,
35,
1511
]
],
[
[
1454,
1,
704
],
[
704,
35,
1511
]
],
[
[
1454,
24,
537
],
[
537,
64,
675
],
[
675,
24,
1511
]
]
] | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound)",
"Alfentanil"
],
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
]
] | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Mepenzolate (Compound)
Sufentanil (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mepenzolate (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil (Compound) resembles Alfentanil (Compound) and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Mepenzolate (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate |
DB00283 | DB00476 | 701 | 109 | [
"DDInter395",
"DDInter608"
] | Clemastine | Duloxetine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Moderate | 1 | [
[
[
701,
24,
109
]
],
[
[
701,
24,
758
],
[
758,
1,
109
]
],
[
[
701,
6,
12523
],
[
12523,
45,
109
]
],
[
[
701,
7,
1986
],
[
1986,
46,
109
]
],
[
[
701,
21,
28936
],
[
28936,
60,
109
]
],
[
[
701,
24,
717
],
[
717,
63,
109
]
],
[
[
701,
24,
1233
],
[
1233,
24,
109
]
],
[
[
701,
35,
1594
],
[
1594,
24,
109
]
],
[
[
701,
24,
1264
],
[
1264,
64,
109
]
],
[
[
701,
24,
758
],
[
758,
40,
847
],
[
847,
1,
109
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Duloxetine (Compound)
Clemastine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Duloxetine (Compound)
Clemastine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Duloxetine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Duloxetine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Duloxetine (Compound) |
DB00559 | DB08907 | 152 | 1,344 | [
"DDInter223",
"DDInter280"
] | Bosentan | Canagliflozin | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
152,
24,
1344
]
],
[
[
152,
24,
549
],
[
549,
1,
1344
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
152,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
152,
24,
1033
],
[
1033,
63,
1344
]
],
[
[
152,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
152,
63,
245
],
[
245,
24,
1344
]
],
[
[
152,
25,
1019
],
[
1019,
63,
1344
]
],
[
[
152,
62,
168
],
[
168,
24,
1344
]
],
[
[
152,
25,
303
],
[
303,
24,
1344
]
]
] | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Bosentan (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Bosentan may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Bosentan may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB08901 | DB09104 | 1,468 | 286 | [
"DDInter1492",
"DDInter1118"
] | Ponatinib | Magnesium hydroxide | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Minor | 0 | [
[
[
1468,
23,
286
]
],
[
[
1468,
63,
109
],
[
109,
23,
286
]
],
[
[
1468,
62,
752
],
[
752,
23,
286
]
],
[
[
1468,
64,
831
],
[
831,
23,
286
]
],
[
[
1468,
64,
859
],
[
859,
24,
286
]
],
[
[
1468,
63,
1593
],
[
1593,
24,
286
]
],
[
[
1468,
62,
1283
],
[
1283,
24,
286
]
],
[
[
1468,
24,
230
],
[
230,
63,
286
]
],
[
[
1468,
24,
1040
],
[
1040,
24,
286
]
],
[
[
1468,
25,
927
],
[
927,
63,
286
]
]
] | [
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
],
[
"Relugolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ponatinib may lead to a major life threatening interaction when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ponatinib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix and Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ponatinib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB01234 | DB06655 | 1,220 | 5 | [
"DDInter513",
"DDInter1077"
] | Dexamethasone | Liraglutide | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
1220,
24,
5
]
],
[
[
1220,
40,
1103
],
[
1103,
23,
5
]
],
[
[
1220,
63,
743
],
[
743,
23,
5
]
],
[
[
1220,
63,
915
],
[
915,
24,
5
]
],
[
[
1220,
24,
651
],
[
651,
24,
5
]
],
[
[
1220,
24,
192
],
[
192,
63,
5
]
],
[
[
1220,
40,
870
],
[
870,
24,
5
]
],
[
[
1220,
62,
480
],
[
480,
24,
5
]
],
[
[
1220,
64,
1299
],
[
1299,
24,
5
]
],
[
[
1220,
25,
1019
],
[
1019,
63,
5
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
]
] | Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide |
DB01222 | DB14723 | 617 | 159 | [
"DDInter246",
"DDInter1026"
] | Budesonide | Larotrectinib | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
617,
24,
159
]
],
[
[
617,
24,
1375
],
[
1375,
24,
159
]
],
[
[
617,
24,
1412
],
[
1412,
63,
159
]
],
[
[
617,
63,
597
],
[
597,
24,
159
]
],
[
[
617,
23,
659
],
[
659,
24,
159
]
],
[
[
617,
40,
1486
],
[
1486,
24,
159
]
],
[
[
617,
62,
455
],
[
455,
24,
159
]
],
[
[
617,
25,
676
],
[
676,
63,
159
]
],
[
[
617,
25,
976
],
[
976,
24,
159
]
],
[
[
617,
25,
1327
],
[
1327,
25,
159
]
]
] | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
]
] | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Budesonide may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Larotrectinib |
DB00719 | DB01173 | 1,219 | 358 | [
"DDInter149",
"DDInter1349"
] | Azatadine | Orphenadrine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1219,
24,
358
]
],
[
[
1219,
24,
211
],
[
211,
1,
358
]
],
[
[
1219,
24,
272
],
[
272,
24,
358
]
],
[
[
1219,
63,
758
],
[
758,
40,
358
]
],
[
[
1219,
24,
1405
],
[
1405,
40,
358
]
],
[
[
1219,
64,
675
],
[
675,
40,
358
]
],
[
[
1219,
74,
21
],
[
21,
1,
358
]
],
[
[
1219,
63,
357
],
[
357,
1,
358
]
],
[
[
1219,
63,
128
],
[
128,
24,
358
]
],
[
[
1219,
24,
849
],
[
849,
63,
358
]
]
] | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
]
] | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Orphenadrine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Orphenadrine (Compound)
Azatadine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Orphenadrine (Compound)
Azatadine (Compound) resembles Amitriptyline (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Orphenadrine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine (Compound) resembles Orphenadrine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine |
DB00196 | DB09080 | 600 | 144 | [
"DDInter743",
"DDInter1331"
] | Fluconazole | Olodaterol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
600,
24,
144
]
],
[
[
600,
23,
1247
],
[
1247,
23,
144
]
],
[
[
600,
24,
956
],
[
956,
24,
144
]
],
[
[
600,
23,
504
],
[
504,
24,
144
]
],
[
[
600,
25,
1011
],
[
1011,
24,
144
]
],
[
[
600,
63,
534
],
[
534,
24,
144
]
],
[
[
600,
24,
1399
],
[
1399,
63,
144
]
],
[
[
600,
25,
880
],
[
880,
63,
144
]
],
[
[
600,
35,
1622
],
[
1622,
24,
144
]
],
[
[
600,
25,
877
],
[
877,
64,
144
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
]
] | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fluconazole may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Olodaterol |
DB09020 | DB09481 | 28 | 460 | [
"DDInter212",
"DDInter1113"
] | Bisacodyl | Magnesium carbonate | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
28,
24,
460
]
],
[
[
28,
63,
355
],
[
355,
23,
460
]
],
[
[
28,
63,
594
],
[
594,
24,
460
]
],
[
[
28,
24,
286
],
[
286,
24,
460
]
],
[
[
28,
63,
355
],
[
355,
63,
216
],
[
216,
23,
460
]
],
[
[
28,
63,
954
],
[
954,
40,
664
],
[
664,
23,
460
]
],
[
[
28,
63,
216
],
[
216,
35,
401
],
[
401,
23,
460
]
],
[
[
28,
63,
684
],
[
684,
36,
401
],
[
401,
23,
460
]
],
[
[
28,
63,
17
],
[
17,
25,
401
],
[
401,
23,
460
]
],
[
[
28,
63,
739
],
[
739,
24,
401
],
[
401,
23,
460
]
]
] | [
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
]
] | Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Promethazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate |
DB01124 | DB04398 | 1,411 | 193 | [
"DDInter1828",
"DDInter1015"
] | Tolbutamide | Lactic acid | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. It is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3. Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020. | Minor | 0 | [
[
[
1411,
23,
193
]
],
[
[
1411,
1,
959
],
[
959,
23,
193
]
],
[
[
1411,
24,
22
],
[
22,
24,
193
]
],
[
[
1411,
63,
1479
],
[
1479,
24,
193
]
],
[
[
1411,
1,
959
],
[
959,
24,
22
],
[
22,
24,
193
]
],
[
[
1411,
24,
22
],
[
22,
63,
590
],
[
590,
23,
193
]
],
[
[
1411,
63,
1479
],
[
1479,
64,
663
],
[
663,
23,
193
]
],
[
[
1411,
6,
10612
],
[
10612,
45,
663
],
[
663,
23,
193
]
],
[
[
1411,
63,
1445
],
[
1445,
63,
590
],
[
590,
23,
193
]
],
[
[
1411,
1,
959
],
[
959,
63,
1479
],
[
1479,
24,
193
]
]
] | [
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactic acid"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactic acid"
]
]
] | Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Lactic acid
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Lactic acid
Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Lactic acid
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Tolbutamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Methotrexate (Compound) and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Lactic acid
Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Lactic acid |
DB00193 | DB06704 | 534 | 247 | [
"DDInter1841",
"DDInter952"
] | Tramadol | Iobenguane (I-131) | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
534,
25,
247
]
],
[
[
534,
6,
7390
],
[
7390,
45,
247
]
],
[
[
534,
21,
28787
],
[
28787,
60,
247
]
],
[
[
534,
25,
820
],
[
820,
24,
247
]
],
[
[
534,
25,
1629
],
[
1629,
64,
247
]
],
[
[
534,
25,
497
],
[
497,
25,
247
]
],
[
[
534,
1,
1100
],
[
1100,
37,
247
]
],
[
[
534,
25,
1048
],
[
1048,
37,
247
]
],
[
[
534,
6,
7390
],
[
7390,
45,
851
],
[
851,
24,
247
]
],
[
[
534,
21,
28787
],
[
28787,
60,
563
],
[
563,
24,
247
]
]
] | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} (Compound) resembles {v} (Compound)",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxapram"
],
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
]
] | Tramadol may lead to a major life threatening interaction when taken with Iobenguane
Tramadol (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Tramadol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Tramadol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Tramadol may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane
Tramadol may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Iobenguane
Tramadol (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Venlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Tramadol may lead to a major life threatening interaction when taken with Doxapram and Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Doxapram may lead to a major life threatening interaction when taken with Iobenguane
Tramadol (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Tramadol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane |
DB06674 | DB08889 | 908 | 350 | [
"DDInter837",
"DDInter299"
] | Golimumab | Carfilzomib | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Major | 2 | [
[
[
908,
25,
350
]
],
[
[
908,
24,
1270
],
[
1270,
63,
350
]
],
[
[
908,
25,
1060
],
[
1060,
63,
350
]
],
[
[
908,
64,
482
],
[
482,
24,
350
]
],
[
[
908,
25,
310
],
[
310,
24,
350
]
],
[
[
908,
63,
1451
],
[
1451,
24,
350
]
],
[
[
908,
24,
1593
],
[
1593,
24,
350
]
],
[
[
908,
62,
1461
],
[
1461,
24,
350
]
],
[
[
908,
64,
581
],
[
581,
25,
350
]
],
[
[
908,
25,
1510
],
[
1510,
25,
350
]
]
] | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
]
] | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may lead to a major life threatening interaction when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Golimumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Carfilzomib
Golimumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Carfilzomib |
DB00477 | DB01233 | 216 | 1,311 | [
"DDInter363",
"DDInter1197"
] | Chlorpromazine | Metoclopramide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Major | 2 | [
[
[
216,
25,
1311
]
],
[
[
216,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
216,
25,
1425
],
[
1425,
40,
1311
]
],
[
[
216,
6,
5289
],
[
5289,
45,
1311
]
],
[
[
216,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
216,
63,
1010
],
[
1010,
23,
1311
]
],
[
[
216,
24,
1383
],
[
1383,
63,
1311
]
],
[
[
216,
24,
662
],
[
662,
24,
1311
]
],
[
[
216,
63,
128
],
[
128,
24,
1311
]
],
[
[
216,
1,
1237
],
[
1237,
63,
1311
]
]
] | [
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} (Compound) resembles {v} (Compound)",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} (Compound) resembles {v} (Compound)",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"DRD3"
],
[
"DRD3",
"{u} (Gene) is bound by {v} (Compound)",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
]
] | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Chlorpromazine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Chlorpromazine (Compound) binds DRD3 (Gene) and DRD3 (Gene) is bound by Metoclopramide (Compound)
Chlorpromazine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide |
DB00603 | DB00982 | 303 | 1,517 | [
"DDInter1137",
"DDInter991"
] | Medroxyprogesterone acetate | Isotretinoin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959. | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-containing product was FDA approved on 7 May 1982. | Moderate | 1 | [
[
[
303,
24,
1517
]
],
[
[
303,
64,
640
],
[
640,
25,
1517
]
],
[
[
303,
7,
2475
],
[
2475,
46,
1517
]
],
[
[
303,
18,
8781
],
[
8781,
57,
1517
]
],
[
[
303,
21,
29537
],
[
29537,
60,
1517
]
],
[
[
303,
63,
362
],
[
362,
24,
1517
]
],
[
[
303,
24,
868
],
[
868,
63,
1517
]
],
[
[
303,
40,
1486
],
[
1486,
24,
1517
]
],
[
[
303,
24,
932
],
[
932,
24,
1517
]
],
[
[
303,
25,
1604
],
[
1604,
63,
1517
]
]
] | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) upregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) downregulates {v} (Gene)",
"ST7"
],
[
"ST7",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Cerebral haemorrhage"
],
[
"Cerebral haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
]
] | Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin
Medroxyprogesterone acetate (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Isotretinoin (Compound)
Medroxyprogesterone acetate (Compound) downregulates ST7 (Gene) and ST7 (Gene) is downregulated by Isotretinoin (Compound)
Medroxyprogesterone acetate (Compound) causes Cerebral haemorrhage (Side Effect) and Cerebral haemorrhage (Side Effect) is caused by Isotretinoin (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin
Medroxyprogesterone acetate (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin
Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin |
DB01169 | DB06288 | 57 | 607 | [
"DDInter120",
"DDInter77"
] | Arsenic trioxide | Amisulpride | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys. | Major | 2 | [
[
[
57,
25,
607
]
],
[
[
57,
62,
112
],
[
112,
23,
607
]
],
[
[
57,
64,
1352
],
[
1352,
24,
607
]
],
[
[
57,
63,
1559
],
[
1559,
24,
607
]
],
[
[
57,
25,
1383
],
[
1383,
63,
607
]
],
[
[
57,
24,
144
],
[
144,
63,
607
]
],
[
[
57,
25,
1231
],
[
1231,
24,
607
]
],
[
[
57,
25,
351
],
[
351,
64,
607
]
],
[
[
57,
64,
401
],
[
401,
25,
607
]
],
[
[
57,
25,
820
],
[
820,
25,
607
]
]
] | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin Immune Fab (Ovine)"
],
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
]
] | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Digoxin Immune Fab (Ovine) and Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Amisulpride
Arsenic trioxide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may lead to a major life threatening interaction when taken with Amisulpride |
DB00501 | DB09034 | 752 | 1,313 | [
"DDInter380",
"DDInter1733"
] | Cimetidine | Suvorexant | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
752,
24,
1313
]
],
[
[
752,
23,
1135
],
[
1135,
62,
1313
]
],
[
[
752,
25,
1213
],
[
1213,
24,
1313
]
],
[
[
752,
24,
1362
],
[
1362,
63,
1313
]
],
[
[
752,
24,
792
],
[
792,
24,
1313
]
],
[
[
752,
63,
254
],
[
254,
24,
1313
]
],
[
[
752,
23,
263
],
[
263,
24,
1313
]
],
[
[
752,
25,
1670
],
[
1670,
63,
1313
]
],
[
[
752,
24,
1419
],
[
1419,
25,
1313
]
],
[
[
752,
23,
609
],
[
609,
25,
1313
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
]
] | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Suvorexant
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Suvorexant |
DB00030 | DB00489 | 1,685 | 17 | [
"DDInter934",
"DDInter1704"
] | Insulin human | Sotalol | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Moderate | 1 | [
[
[
1685,
24,
17
]
],
[
[
1685,
24,
88
],
[
88,
40,
17
]
],
[
[
1685,
24,
417
],
[
417,
23,
17
]
],
[
[
1685,
24,
1479
],
[
1479,
62,
17
]
],
[
[
1685,
24,
966
],
[
966,
24,
17
]
],
[
[
1685,
24,
1446
],
[
1446,
63,
17
]
],
[
[
1685,
24,
1154
],
[
1154,
64,
17
]
],
[
[
1685,
24,
1424
],
[
1424,
25,
17
]
],
[
[
1685,
63,
521
],
[
521,
25,
17
]
],
[
[
1685,
24,
1148
],
[
1148,
74,
17
]
]
] | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
]
] | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Sotalol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline (Compound) resembles Sotalol (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sotalol |
DB00196 | DB06788 | 600 | 1,616 | [
"DDInter743",
"DDInter864"
] | Fluconazole | Histrelin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
600,
24,
1616
]
],
[
[
600,
23,
112
],
[
112,
23,
1616
]
],
[
[
600,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
600,
24,
603
],
[
603,
63,
1616
]
],
[
[
600,
25,
927
],
[
927,
63,
1616
]
],
[
[
600,
25,
594
],
[
594,
24,
1616
]
],
[
[
600,
63,
317
],
[
317,
24,
1616
]
],
[
[
600,
23,
479
],
[
479,
24,
1616
]
],
[
[
600,
35,
1622
],
[
1622,
24,
1616
]
],
[
[
600,
25,
57
],
[
57,
25,
1616
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vasopressin"
],
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
]
] | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Vasopressin and Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Fluconazole may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin |
DB00877 | DB08904 | 629 | 375 | [
"DDInter1678",
"DDInter342"
] | Sirolimus | Certolizumab pegol | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
629,
25,
375
]
],
[
[
629,
62,
1461
],
[
1461,
23,
375
]
],
[
[
629,
23,
1193
],
[
1193,
62,
375
]
],
[
[
629,
63,
704
],
[
704,
24,
375
]
],
[
[
629,
24,
200
],
[
200,
63,
375
]
],
[
[
629,
24,
1554
],
[
1554,
24,
375
]
],
[
[
629,
64,
759
],
[
759,
24,
375
]
],
[
[
629,
25,
697
],
[
697,
24,
375
]
],
[
[
629,
64,
1066
],
[
1066,
25,
375
]
],
[
[
629,
63,
870
],
[
870,
25,
375
]
]
] | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sirolimus may lead to a major life threatening interaction when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sirolimus may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Sirolimus may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00366 | DB01175 | 1,594 | 318 | [
"DDInter600",
"DDInter672"
] | Doxylamine | Escitalopram | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
1594,
24,
318
]
],
[
[
1594,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1594,
6,
10104
],
[
10104,
45,
318
]
],
[
[
1594,
21,
29579
],
[
29579,
60,
318
]
],
[
[
1594,
24,
999
],
[
999,
24,
318
]
],
[
[
1594,
24,
1609
],
[
1609,
63,
318
]
],
[
[
1594,
63,
475
],
[
475,
24,
318
]
],
[
[
1594,
35,
272
],
[
272,
24,
318
]
],
[
[
1594,
74,
701
],
[
701,
24,
318
]
],
[
[
1594,
24,
401
],
[
401,
25,
318
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Breast disorder"
],
[
"Breast disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Doxylamine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Escitalopram (Compound)
Doxylamine (Compound) causes Breast disorder (Side Effect) and Breast disorder (Side Effect) is caused by Escitalopram (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Escitalopram |
DB00270 | DB05679 | 1,428 | 1,683 | [
"DDInter993",
"DDInter1907"
] | Isradipine | Ustekinumab | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
1428,
24,
1683
]
],
[
[
1428,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
1428,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
1428,
1,
409
],
[
409,
24,
1683
]
],
[
[
1428,
23,
467
],
[
467,
24,
1683
]
],
[
[
1428,
63,
1648
],
[
1648,
24,
1683
]
],
[
[
1428,
40,
854
],
[
854,
24,
1683
]
],
[
[
1428,
24,
1583
],
[
1583,
64,
1683
]
],
[
[
1428,
63,
1057
],
[
1057,
25,
1683
]
],
[
[
1428,
24,
1042
],
[
1042,
24,
1129
],
[
1129,
63,
1683
]
]
] | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
],
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
]
] | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may lead to a major life threatening interaction when taken with Ustekinumab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab |
DB00207 | DB09330 | 1,570 | 985 | [
"DDInter157",
"DDInter1352"
] | Azithromycin | Osimertinib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
1570,
25,
985
]
],
[
[
1570,
23,
112
],
[
112,
23,
985
]
],
[
[
1570,
24,
480
],
[
480,
24,
985
]
],
[
[
1570,
24,
119
],
[
119,
63,
985
]
],
[
[
1570,
25,
11
],
[
11,
25,
985
]
],
[
[
1570,
24,
594
],
[
594,
25,
985
]
],
[
[
1570,
24,
484
],
[
484,
64,
985
]
],
[
[
1570,
25,
351
],
[
351,
64,
985
]
],
[
[
1570,
63,
521
],
[
521,
25,
985
]
],
[
[
1570,
40,
1056
],
[
1056,
25,
985
]
]
] | [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
],
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Azithromycin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Osimertinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Azithromycin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osimertinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Osimertinib
Azithromycin (Compound) resembles Telithromycin (Compound) and Telithromycin may lead to a major life threatening interaction when taken with Osimertinib |
DB00059 | DB00352 | 1,560 | 482 | [
"DDInter1404",
"DDInter1814"
] | Pegaspargase | Tioguanine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
1560,
24,
482
]
],
[
[
1560,
24,
1299
],
[
1299,
62,
482
]
],
[
[
1560,
24,
151
],
[
151,
63,
482
]
],
[
[
1560,
24,
1324
],
[
1324,
24,
482
]
],
[
[
1560,
63,
1648
],
[
1648,
24,
482
]
],
[
[
1560,
25,
1101
],
[
1101,
24,
482
]
],
[
[
1560,
25,
581
],
[
581,
25,
482
]
],
[
[
1560,
25,
334
],
[
334,
64,
482
]
],
[
[
1560,
64,
1057
],
[
1057,
25,
482
]
],
[
[
1560,
24,
328
],
[
328,
74,
482
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Pegaspargase may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tioguanine
Pegaspargase may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Tioguanine
Pegaspargase may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tioguanine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine (Compound) resembles Tioguanine (Compound) and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine |
DB00254 | DB00524 | 964 | 811 | [
"DDInter598",
"DDInter1199"
] | Doxycycline | Metolazone | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria. | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Minor | 0 | [
[
[
964,
23,
811
]
],
[
[
964,
23,
1605
],
[
1605,
40,
811
]
],
[
[
964,
23,
1014
],
[
1014,
1,
811
]
],
[
[
964,
40,
1620
],
[
1620,
62,
811
]
],
[
[
964,
1,
1669
],
[
1669,
62,
811
]
],
[
[
964,
24,
126
],
[
126,
62,
811
]
],
[
[
964,
24,
1296
],
[
1296,
63,
811
]
],
[
[
964,
63,
1685
],
[
1685,
24,
811
]
],
[
[
964,
24,
666
],
[
666,
24,
811
]
],
[
[
964,
25,
213
],
[
213,
64,
811
]
]
] | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium acetate"
],
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Doxycycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metolazone"
]
]
] | Doxycycline may cause a minor interaction that can limit clinical effects when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Metolazone (Compound)
Doxycycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Metolazone
Doxycycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when taken with Metolazone
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Metolazone
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate and Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Doxycycline may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Metolazone |
DB00305 | DB12010 | 377 | 214 | [
"DDInter1232",
"DDInter785"
] | Mitomycin | Fostamatinib | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
377,
24,
214
]
],
[
[
377,
25,
976
],
[
976,
24,
214
]
],
[
[
377,
24,
51
],
[
51,
24,
214
]
],
[
[
377,
25,
676
],
[
676,
63,
214
]
],
[
[
377,
23,
255
],
[
255,
24,
214
]
],
[
[
377,
25,
1292
],
[
1292,
25,
214
]
],
[
[
377,
25,
976
],
[
976,
63,
723
],
[
723,
24,
214
]
],
[
[
377,
24,
51
],
[
51,
25,
976
],
[
976,
24,
214
]
],
[
[
377,
24,
597
],
[
597,
24,
723
],
[
723,
24,
214
]
],
[
[
377,
24,
1362
],
[
1362,
64,
976
],
[
976,
24,
214
]
]
] | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
] | Mitomycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Fostamatinib
Mitomycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB11817 | DB12240 | 1,259 | 110 | [
"DDInter165",
"DDInter1485"
] | Baricitinib | Polatuzumab vedotin | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020. | Major | 2 | [
[
[
1259,
25,
110
]
],
[
[
1259,
64,
1419
],
[
1419,
24,
110
]
],
[
[
1259,
63,
810
],
[
810,
24,
110
]
],
[
[
1259,
25,
270
],
[
270,
24,
110
]
],
[
[
1259,
25,
1619
],
[
1619,
63,
110
]
],
[
[
1259,
64,
507
],
[
507,
25,
110
]
],
[
[
1259,
25,
676
],
[
676,
64,
110
]
],
[
[
1259,
64,
1419
],
[
1419,
25,
129
],
[
129,
23,
110
]
],
[
[
1259,
64,
268
],
[
268,
24,
467
],
[
467,
24,
110
]
],
[
[
1259,
64,
980
],
[
980,
63,
467
],
[
467,
24,
110
]
]
] | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
]
] | Baricitinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin |
DB11791 | DB11979 | 785 | 1,320 | [
"DDInter287",
"DDInter625"
] | Capmatinib | Elagolix | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
785,
24,
1320
]
],
[
[
785,
63,
608
],
[
608,
23,
1320
]
],
[
[
785,
64,
129
],
[
129,
24,
1320
]
],
[
[
785,
63,
372
],
[
372,
24,
1320
]
],
[
[
785,
25,
913
],
[
913,
24,
1320
]
],
[
[
785,
24,
159
],
[
159,
63,
1320
]
],
[
[
785,
25,
1017
],
[
1017,
63,
1320
]
],
[
[
785,
24,
738
],
[
738,
24,
1320
]
],
[
[
785,
62,
1135
],
[
1135,
24,
1320
]
],
[
[
785,
64,
760
],
[
760,
25,
1320
]
]
] | [
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Capmatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
]
] | Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Capmatinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Capmatinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Elagolix |
DB00486 | DB04837 | 1,614 | 649 | [
"DDInter1253",
"DDInter407"
] | Nabilone | Clofedanol | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1614,
24,
649
]
],
[
[
1614,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1614,
63,
21
],
[
21,
24,
649
]
],
[
[
1614,
25,
675
],
[
675,
40,
649
]
],
[
[
1614,
24,
832
],
[
832,
40,
649
]
],
[
[
1614,
63,
508
],
[
508,
40,
649
]
],
[
[
1614,
24,
1313
],
[
1313,
63,
649
]
],
[
[
1614,
40,
530
],
[
530,
24,
649
]
],
[
[
1614,
24,
662
],
[
662,
35,
649
]
],
[
[
1614,
63,
576
],
[
576,
35,
649
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
],
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
]
] | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Nabilone may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Clofedanol (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Clofedanol (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Clofedanol (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant and Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Clofedanol (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol |
DB05679 | DB06228 | 1,683 | 792 | [
"DDInter1907",
"DDInter1609"
] | Ustekinumab | Rivaroxaban | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Moderate | 1 | [
[
[
1683,
24,
792
]
],
[
[
1683,
63,
453
],
[
453,
40,
792
]
],
[
[
1683,
24,
1303
],
[
1303,
63,
792
]
],
[
[
1683,
63,
597
],
[
597,
24,
792
]
],
[
[
1683,
25,
980
],
[
980,
63,
792
]
],
[
[
1683,
64,
581
],
[
581,
24,
792
]
],
[
[
1683,
24,
1531
],
[
1531,
24,
792
]
],
[
[
1683,
62,
1461
],
[
1461,
24,
792
]
],
[
[
1683,
63,
759
],
[
759,
25,
792
]
],
[
[
1683,
24,
397
],
[
397,
64,
792
]
]
] | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
],
[
"Linezolid",
"{u} (Compound) resembles {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
],
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
]
] | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid (Compound) resembles Rivaroxaban (Compound)
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may lead to a major life threatening interaction when taken with Rivaroxaban
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin and Plicamycin may lead to a major life threatening interaction when taken with Rivaroxaban |
DB00372 | DB01181 | 999 | 1,532 | [
"DDInter1793",
"DDInter906"
] | Thiethylperazine | Ifosfamide | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
999,
24,
1532
]
],
[
[
999,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
999,
25,
684
],
[
684,
24,
1532
]
],
[
[
999,
24,
1170
],
[
1170,
24,
1532
]
],
[
[
999,
24,
154
],
[
154,
63,
1532
]
],
[
[
999,
64,
534
],
[
534,
24,
1532
]
],
[
[
999,
25,
1311
],
[
1311,
63,
1532
]
],
[
[
999,
25,
497
],
[
497,
64,
1532
]
],
[
[
999,
63,
695
],
[
695,
25,
1532
]
],
[
[
999,
24,
770
],
[
770,
25,
1532
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
],
[
"Amantadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Amantadine and Amantadine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Ifosfamide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Ifosfamide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide |
DB00582 | DB06605 | 1,622 | 1,409 | [
"DDInter1946",
"DDInter108"
] | Voriconazole | Apixaban | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms. Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
1622,
25,
1409
]
],
[
[
1622,
6,
10215
],
[
10215,
45,
1409
]
],
[
[
1622,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
1622,
25,
1670
],
[
1670,
63,
1409
]
],
[
[
1622,
24,
86
],
[
86,
24,
1409
]
],
[
[
1622,
24,
1040
],
[
1040,
63,
1409
]
],
[
[
1622,
63,
1560
],
[
1560,
24,
1409
]
],
[
[
1622,
64,
1101
],
[
1101,
24,
1409
]
],
[
[
1622,
74,
600
],
[
600,
24,
1409
]
],
[
[
1622,
25,
392
],
[
392,
24,
1409
]
]
] | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Melaena"
],
[
"Melaena",
"{u} (Side Effect) is caused by {v} (Compound)",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
]
] | Voriconazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Apixaban (Compound)
Voriconazole (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole (Compound) resembles Fluconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Voriconazole may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban |
DB00286 | DB00731 | 380 | 1,144 | [
"DDInter439",
"DDInter1269"
] | Conjugated estrogens | Nateglinide | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.[L5605, T475] The conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. | Moderate | 1 | [
[
[
380,
24,
1144
]
],
[
[
380,
6,
9320
],
[
9320,
45,
1144
]
],
[
[
380,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
380,
24,
1051
],
[
1051,
23,
1144
]
],
[
[
380,
24,
609
],
[
609,
63,
1144
]
],
[
[
380,
24,
542
],
[
542,
24,
1144
]
],
[
[
380,
40,
559
],
[
559,
24,
1144
]
],
[
[
380,
63,
245
],
[
245,
24,
1144
]
],
[
[
380,
40,
1438
],
[
1438,
63,
1144
]
],
[
[
380,
1,
35
],
[
35,
63,
1144
]
]
] | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCC4"
],
[
"ABCC4",
"{u} (Gene) is bound by {v} (Compound)",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
]
] | Conjugated estrogens (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Nateglinide (Compound)
Conjugated estrogens (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Nateglinide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Conjugated estrogens (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Conjugated estrogens (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide |
DB00252 | DB09112 | 362 | 1,455 | [
"DDInter1460",
"DDInter1306"
] | Phenytoin | Nitrous acid | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections. | Major | 2 | [
[
[
362,
25,
1455
]
],
[
[
362,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
362,
24,
433
],
[
433,
63,
1455
]
],
[
[
362,
1,
697
],
[
697,
25,
1455
]
],
[
[
362,
24,
1311
],
[
1311,
25,
1455
]
],
[
[
362,
23,
608
],
[
608,
25,
1455
]
],
[
[
362,
24,
1450
],
[
1450,
63,
312
],
[
312,
24,
1455
]
],
[
[
362,
24,
1061
],
[
1061,
24,
312
],
[
312,
24,
1455
]
],
[
[
362,
1,
697
],
[
697,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
362,
23,
608
],
[
608,
23,
152
],
[
152,
24,
1455
]
]
] | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
]
] | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenytoin (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Nitrous acid
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Nitrous acid
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may lead to a major life threatening interaction when taken with Nitrous acid
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenytoin (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bosentan and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid |
DB00405 | DB01219 | 128 | 716 | [
"DDInter517",
"DDInter473"
] | Dexbrompheniramine | Dantrolene | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
128,
24,
716
]
],
[
[
128,
24,
1609
],
[
1609,
63,
716
]
],
[
[
128,
24,
100
],
[
100,
24,
716
]
],
[
[
128,
63,
1242
],
[
1242,
24,
716
]
],
[
[
128,
74,
1594
],
[
1594,
24,
716
]
],
[
[
128,
63,
475
],
[
475,
25,
716
]
],
[
[
128,
24,
1609
],
[
1609,
63,
100
],
[
100,
24,
716
]
],
[
[
128,
24,
100
],
[
100,
6,
8374
],
[
8374,
45,
716
]
],
[
[
128,
24,
13
],
[
13,
21,
28698
],
[
28698,
60,
716
]
],
[
[
128,
24,
649
],
[
649,
24,
1609
],
[
1609,
63,
716
]
]
] | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dantrolene"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
]
] | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Dantrolene
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene |
DB01259 | DB11730 | 392 | 351 | [
"DDInter1024",
"DDInter1588"
] | Lapatinib | Ribociclib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
392,
25,
351
]
],
[
[
392,
23,
271
],
[
271,
23,
351
]
],
[
[
392,
24,
466
],
[
466,
62,
351
]
],
[
[
392,
62,
1247
],
[
1247,
23,
351
]
],
[
[
392,
63,
222
],
[
222,
23,
351
]
],
[
[
392,
23,
907
],
[
907,
62,
351
]
],
[
[
392,
24,
1627
],
[
1627,
23,
351
]
],
[
[
392,
63,
402
],
[
402,
24,
351
]
],
[
[
392,
24,
861
],
[
861,
63,
351
]
],
[
[
392,
24,
310
],
[
310,
24,
351
]
]
] | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
]
] | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil and Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib |
DB00347 | DB00358 | 917 | 1,010 | [
"DDInter1871",
"DDInter1140"
] | Trimethadione | Mefloquine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953] | Moderate | 1 | [
[
[
917,
24,
1010
]
],
[
[
917,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
917,
21,
28810
],
[
28810,
60,
1010
]
],
[
[
917,
24,
1311
],
[
1311,
62,
1010
]
],
[
[
917,
24,
401
],
[
401,
63,
1010
]
],
[
[
917,
24,
1487
],
[
1487,
64,
1010
]
],
[
[
917,
6,
8374
],
[
8374,
45,
1620
],
[
1620,
62,
1010
]
],
[
[
917,
21,
28810
],
[
28810,
60,
782
],
[
782,
40,
1010
]
],
[
[
917,
21,
29091
],
[
29091,
60,
112
],
[
112,
62,
1010
]
],
[
[
917,
24,
1311
],
[
1311,
6,
12523
],
[
12523,
45,
1010
]
]
] | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flecainide"
],
[
"Flecainide",
"{u} (Compound) resembles {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Aplastic anaemia"
],
[
"Aplastic anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
]
] | Trimethadione (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Trimethadione (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Mefloquine (Compound)
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Mefloquine
Trimethadione (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Trimethadione (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Trimethadione (Compound) causes Aplastic anaemia (Side Effect) and Aplastic anaemia (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) |
DB00321 | DB09278 | 21 | 852 | [
"DDInter78",
"DDInter24"
] | Amitriptyline | Activated charcoal | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances. It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive oral ingestion of certain medications or poisons by absorbing most drugs and toxins. However its effects is rendered poor on some compounds including strong acids or bases, methanol and substances with limited absorptive capacity (including iron, lithium, arsenic). It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. The clinical applications of activated charcoal occured in the early 1800's. While this management for acute poisoning is considered fairly invasive, it is on the World Health Organization's List of Essential Medicines that includes the most important medications needed in a basic health system. | Moderate | 1 | [
[
[
21,
24,
852
]
],
[
[
21,
24,
1411
],
[
1411,
24,
852
]
],
[
[
21,
40,
1164
],
[
1164,
24,
852
]
],
[
[
21,
35,
1264
],
[
1264,
24,
852
]
],
[
[
21,
1,
1335
],
[
1335,
24,
852
]
],
[
[
21,
24,
1411
],
[
1411,
63,
127
],
[
127,
24,
852
]
],
[
[
21,
40,
1164
],
[
1164,
24,
1411
],
[
1411,
24,
852
]
],
[
[
21,
35,
1264
],
[
1264,
63,
1411
],
[
1411,
24,
852
]
],
[
[
21,
1,
1335
],
[
1335,
24,
1411
],
[
1411,
24,
852
]
],
[
[
21,
24,
590
],
[
590,
24,
127
],
[
127,
24,
852
]
]
] | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
]
] | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Doxepin (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Doxepin (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal |
DB11730 | DB12941 | 351 | 466 | [
"DDInter1588",
"DDInter481"
] | Ribociclib | Darolutamide | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Minor | 0 | [
[
[
351,
23,
466
]
],
[
[
351,
64,
1622
],
[
1622,
23,
466
]
],
[
[
351,
63,
1623
],
[
1623,
23,
466
]
],
[
[
351,
23,
283
],
[
283,
23,
466
]
],
[
[
351,
25,
484
],
[
484,
23,
466
]
],
[
[
351,
24,
800
],
[
800,
23,
466
]
],
[
[
351,
24,
159
],
[
159,
62,
466
]
],
[
[
351,
25,
68
],
[
68,
62,
466
]
],
[
[
351,
24,
738
],
[
738,
24,
466
]
],
[
[
351,
63,
1040
],
[
1040,
24,
466
]
]
] | [
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
]
] | Ribociclib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide |
DB00358 | DB01177 | 1,010 | 77 | [
"DDInter1140",
"DDInter904"
] | Mefloquine | Idarubicin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1010,
24,
77
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
77
]
],
[
[
1010,
18,
2183
],
[
2183,
57,
77
]
],
[
[
1010,
7,
5998
],
[
5998,
57,
77
]
],
[
[
1010,
21,
28987
],
[
28987,
60,
77
]
],
[
[
1010,
24,
739
],
[
739,
23,
77
]
],
[
[
1010,
23,
1247
],
[
1247,
23,
77
]
],
[
[
1010,
24,
823
],
[
823,
63,
77
]
],
[
[
1010,
24,
543
],
[
543,
24,
77
]
],
[
[
1010,
64,
534
],
[
534,
24,
77
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
]
] | Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Mefloquine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Idarubicin (Compound)
Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Idarubicin (Compound)
Mefloquine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Mefloquine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin |
DB00754 | DB09054 | 157 | 384 | [
"DDInter696",
"DDInter905"
] | Ethotoin | Idelalisib | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
157,
24,
384
]
],
[
[
157,
24,
222
],
[
222,
23,
384
]
],
[
[
157,
63,
305
],
[
305,
24,
384
]
],
[
[
157,
24,
891
],
[
891,
24,
384
]
],
[
[
157,
64,
600
],
[
600,
24,
384
]
],
[
[
157,
62,
608
],
[
608,
24,
384
]
],
[
[
157,
24,
270
],
[
270,
63,
384
]
],
[
[
157,
63,
134
],
[
134,
25,
384
]
],
[
[
157,
24,
1486
],
[
1486,
25,
384
]
],
[
[
157,
1,
697
],
[
697,
25,
384
]
]
] | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Ethotoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ethotoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ethotoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Idelalisib
Ethotoin (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Idelalisib |
DB00990 | DB12130 | 1,547 | 1,017 | [
"DDInter705",
"DDInter1094"
] | Exemestane | Lorlatinib | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1547,
24,
1017
]
],
[
[
1547,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1547,
63,
629
],
[
629,
24,
1017
]
],
[
[
1547,
24,
214
],
[
214,
24,
1017
]
],
[
[
1547,
24,
1654
],
[
1654,
63,
1017
]
],
[
[
1547,
1,
1573
],
[
1573,
24,
1017
]
],
[
[
1547,
24,
1220
],
[
1220,
25,
1017
]
],
[
[
1547,
63,
1249
],
[
1249,
25,
1017
]
],
[
[
1547,
24,
1375
],
[
1375,
64,
1017
]
],
[
[
1547,
63,
1101
],
[
1101,
62,
608
],
[
608,
23,
1017
]
]
] | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Exemestane (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may lead to a major life threatening interaction when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Lorlatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB00427 | DB00454 | 1,233 | 1,349 | [
"DDInter1879",
"DDInter1150"
] | Triprolidine | Meperidine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Moderate | 1 | [
[
[
1233,
24,
1349
]
],
[
[
1233,
24,
411
],
[
411,
1,
1349
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
1349
]
],
[
[
1233,
24,
100
],
[
100,
63,
1349
]
],
[
[
1233,
63,
128
],
[
128,
24,
1349
]
],
[
[
1233,
24,
13
],
[
13,
24,
1349
]
],
[
[
1233,
24,
1053
],
[
1053,
64,
1349
]
],
[
[
1233,
63,
475
],
[
475,
25,
1349
]
],
[
[
1233,
24,
411
],
[
411,
1,
11366
],
[
11366,
1,
1349
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
41
],
[
41,
1,
1349
]
]
] | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} (Compound) resembles {v} (Compound)",
"Anileridine"
],
[
"Anileridine",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
]
] | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Meperidine (Compound)
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Meperidine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Meperidine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Meperidine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Anileridine (Compound) and Anileridine (Compound) resembles Meperidine (Compound)
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Meperidine (Compound) |
DB00029 | DB12364 | 25 | 1,421 | [
"DDInter99",
"DDInter200"
] | Anistreplase | Betrixaban | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Major | 2 | [
[
[
25,
25,
1421
]
],
[
[
25,
23,
297
],
[
297,
23,
1421
]
],
[
[
25,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
25,
24,
992
],
[
992,
24,
1421
]
],
[
[
25,
24,
972
],
[
972,
63,
1421
]
],
[
[
25,
24,
714
],
[
714,
25,
1421
]
],
[
[
25,
25,
235
],
[
235,
25,
1421
]
],
[
[
25,
25,
1650
],
[
1650,
64,
1421
]
],
[
[
25,
64,
1578
],
[
1578,
25,
1421
]
],
[
[
25,
23,
297
],
[
297,
62,
477
],
[
477,
25,
1421
]
]
] | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
],
[
"Ginger",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
]
] | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Anistreplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginger and Ginger may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Anistreplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Betrixaban
Anistreplase may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Betrixaban
Anistreplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Betrixaban
Anistreplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Betrixaban |
DB00515 | DB01267 | 589 | 519 | [
"DDInter387",
"DDInter1381"
] | Cisplatin | Paliperidone | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Moderate | 1 | [
[
[
589,
24,
519
]
],
[
[
589,
24,
1664
],
[
1664,
1,
519
]
],
[
[
589,
21,
28695
],
[
28695,
60,
519
]
],
[
[
589,
24,
112
],
[
112,
23,
519
]
],
[
[
589,
24,
36
],
[
36,
63,
519
]
],
[
[
589,
24,
51
],
[
51,
24,
519
]
],
[
[
589,
64,
1648
],
[
1648,
24,
519
]
],
[
[
589,
25,
770
],
[
770,
24,
519
]
],
[
[
589,
63,
322
],
[
322,
24,
519
]
],
[
[
589,
25,
1011
],
[
1011,
64,
519
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paliperidone"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Cisplatin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Paliperidone (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Paliperidone
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Cisplatin may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Cisplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Cisplatin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Paliperidone |
DB00451 | DB09104 | 542 | 286 | [
"DDInter1064",
"DDInter1118"
] | Levothyroxine | Magnesium hydroxide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
542,
24,
286
]
],
[
[
542,
24,
1482
],
[
1482,
23,
286
]
],
[
[
542,
62,
88
],
[
88,
23,
286
]
],
[
[
542,
23,
752
],
[
752,
23,
286
]
],
[
[
542,
63,
1252
],
[
1252,
23,
286
]
],
[
[
542,
24,
633
],
[
633,
24,
286
]
],
[
[
542,
63,
362
],
[
362,
24,
286
]
],
[
[
542,
24,
913
],
[
913,
63,
286
]
],
[
[
542,
23,
827
],
[
827,
24,
286
]
],
[
[
542,
40,
1152
],
[
1152,
24,
286
]
]
] | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Trazodone and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00153 | DB09146 | 1,331 | 489 | [
"DDInter662",
"DDInter978"
] | Ergocalciferol | Iron sucrose | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932. Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism. The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 194 | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. | Moderate | 1 | [
[
[
1331,
24,
489
]
],
[
[
1331,
36,
386
],
[
386,
24,
489
]
],
[
[
1331,
64,
160
],
[
160,
24,
489
]
],
[
[
1331,
25,
1196
],
[
1196,
24,
489
]
],
[
[
1331,
25,
241
],
[
241,
64,
489
]
],
[
[
1331,
36,
386
],
[
386,
25,
1041
],
[
1041,
24,
489
]
],
[
[
1331,
36,
1041
],
[
1041,
64,
386
],
[
386,
24,
489
]
],
[
[
1331,
64,
160
],
[
160,
36,
386
],
[
386,
24,
489
]
],
[
[
1331,
25,
1196
],
[
1196,
64,
386
],
[
386,
24,
489
]
],
[
[
1331,
1,
11418
],
[
11418,
1,
386
],
[
386,
24,
489
]
]
] | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound)",
"Alfacalcidol"
],
[
"Alfacalcidol",
"{u} (Compound) resembles {v} (Compound)",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
]
] | Ergocalciferol (Compound) resembles Cholecalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Iron sucrose
Ergocalciferol (Compound) resembles Cholecalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol (Compound) resembles Paricalcitol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Ergocalciferol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Cholecalciferol (Compound) and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose |
DB04845 | DB06372 | 309 | 259 | [
"DDInter1001",
"DDInter1594"
] | Ixabepilone | Rilonacept | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Moderate | 1 | [
[
[
309,
24,
259
]
],
[
[
309,
63,
1461
],
[
1461,
23,
259
]
],
[
[
309,
24,
1619
],
[
1619,
63,
259
]
],
[
[
309,
24,
478
],
[
478,
24,
259
]
],
[
[
309,
63,
651
],
[
651,
24,
259
]
],
[
[
309,
62,
60
],
[
60,
24,
259
]
],
[
[
309,
25,
1011
],
[
1011,
64,
259
]
],
[
[
309,
64,
1377
],
[
1377,
25,
259
]
],
[
[
309,
24,
980
],
[
980,
25,
259
]
],
[
[
309,
63,
1461
],
[
1461,
24,
0
],
[
0,
24,
259
]
]
] | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
],
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
]
] | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Ixabepilone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Rilonacept
Ixabepilone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rilonacept
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Rilonacept
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept |
DB00010 | DB01278 | 1,649 | 1,021 | [
"DDInter1661",
"DDInter1506"
] | Sermorelin | Pramlintide | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1649,
24,
1021
]
],
[
[
1649,
24,
1144
],
[
1144,
24,
1021
]
],
[
[
1649,
24,
1296
],
[
1296,
63,
1021
]
],
[
[
1649,
24,
1144
],
[
1144,
62,
1103
],
[
1103,
23,
1021
]
],
[
[
1649,
24,
176
],
[
176,
23,
1103
],
[
1103,
23,
1021
]
],
[
[
1649,
24,
1144
],
[
1144,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
1649,
24,
176
],
[
176,
24,
1560
],
[
1560,
24,
1021
]
],
[
[
1649,
24,
1144
],
[
1144,
64,
839
],
[
839,
24,
1021
]
],
[
[
1649,
24,
176
],
[
176,
25,
839
],
[
839,
24,
1021
]
],
[
[
1649,
24,
1144
],
[
1144,
24,
708
],
[
708,
63,
1021
]
]
] | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
]
] | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
DB00446 | DB06616 | 597 | 594 | [
"DDInter351",
"DDInter224"
] | Chloramphenicol | Bosutinib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
597,
24,
594
]
],
[
[
597,
63,
883
],
[
883,
1,
594
]
],
[
[
597,
7,
1972
],
[
1972,
45,
594
]
],
[
[
597,
6,
8374
],
[
8374,
45,
594
]
],
[
[
597,
7,
3727
],
[
3727,
46,
594
]
],
[
[
597,
18,
4360
],
[
4360,
57,
594
]
],
[
[
597,
21,
28882
],
[
28882,
60,
594
]
],
[
[
597,
24,
112
],
[
112,
23,
594
]
],
[
[
597,
24,
786
],
[
786,
63,
594
]
],
[
[
597,
25,
1598
],
[
1598,
63,
594
]
]
] | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) upregulates {v} (Gene)",
"PRKCQ"
],
[
"PRKCQ",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) downregulates {v} (Gene)",
"TIMM9"
],
[
"TIMM9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
]
] | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Chloramphenicol (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is bound by Bosutinib (Compound)
Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Chloramphenicol (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Bosutinib (Compound)
Chloramphenicol (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Bosutinib (Compound)
Chloramphenicol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Bosutinib (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Chloramphenicol may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00603 | DB01124 | 303 | 1,411 | [
"DDInter1137",
"DDInter1828"
] | Medroxyprogesterone acetate | Tolbutamide | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
303,
24,
1411
]
],
[
[
303,
24,
959
],
[
959,
40,
1411
]
],
[
[
303,
63,
245
],
[
245,
40,
1411
]
],
[
[
303,
6,
3486
],
[
3486,
45,
1411
]
],
[
[
303,
18,
9205
],
[
9205,
57,
1411
]
],
[
[
303,
21,
28746
],
[
28746,
60,
1411
]
],
[
[
303,
63,
1051
],
[
1051,
23,
1411
]
],
[
[
303,
23,
801
],
[
801,
62,
1411
]
],
[
[
303,
24,
1478
],
[
1478,
63,
1411
]
],
[
[
303,
63,
529
],
[
529,
24,
1411
]
]
] | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) downregulates {v} (Gene)",
"IFRD2"
],
[
"IFRD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
],
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
]
] | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Medroxyprogesterone acetate (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Tolbutamide (Compound)
Medroxyprogesterone acetate (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Tolbutamide (Compound)
Medroxyprogesterone acetate (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Brivaracetam and Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00557 | DB09272 | 252 | 412 | [
"DDInter895",
"DDInter632"
] | Hydroxyzine | Eluxadoline | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
252,
24,
412
]
],
[
[
252,
63,
1594
],
[
1594,
24,
412
]
],
[
[
252,
24,
543
],
[
543,
24,
412
]
],
[
[
252,
64,
475
],
[
475,
24,
412
]
],
[
[
252,
40,
851
],
[
851,
24,
412
]
],
[
[
252,
24,
407
],
[
407,
63,
412
]
],
[
[
252,
1,
623
],
[
623,
24,
412
]
],
[
[
252,
25,
1425
],
[
1425,
24,
412
]
],
[
[
252,
74,
701
],
[
701,
24,
412
]
],
[
[
252,
24,
392
],
[
392,
25,
412
]
]
] | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
]
]
] | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine (Compound) resembles Clemastine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Eluxadoline |
DB09054 | DB11828 | 384 | 1,406 | [
"DDInter905",
"DDInter1281"
] | Idelalisib | Neratinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
384,
25,
1406
]
],
[
[
384,
64,
1135
],
[
1135,
23,
1406
]
],
[
[
384,
64,
392
],
[
392,
24,
1406
]
],
[
[
384,
63,
1195
],
[
1195,
24,
1406
]
],
[
[
384,
24,
710
],
[
710,
63,
1406
]
],
[
[
384,
25,
829
],
[
829,
63,
1406
]
],
[
[
384,
24,
1499
],
[
1499,
24,
1406
]
],
[
[
384,
25,
985
],
[
985,
24,
1406
]
],
[
[
384,
64,
1554
],
[
1554,
25,
1406
]
],
[
[
384,
25,
283
],
[
283,
64,
1406
]
]
] | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Idelalisib may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may lead to a major life threatening interaction when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Idelalisib may lead to a major life threatening interaction when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Neratinib
Idelalisib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib |
DB00877 | DB11921 | 629 | 1,019 | [
"DDInter1678",
"DDInter492"
] | Sirolimus | Deflazacort | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
629,
24,
1019
]
],
[
[
629,
23,
1193
],
[
1193,
23,
1019
]
],
[
[
629,
62,
1461
],
[
1461,
23,
1019
]
],
[
[
629,
24,
959
],
[
959,
24,
1019
]
],
[
[
629,
24,
270
],
[
270,
63,
1019
]
],
[
[
629,
64,
914
],
[
914,
24,
1019
]
],
[
[
629,
25,
1263
],
[
1263,
24,
1019
]
],
[
[
629,
63,
1428
],
[
1428,
24,
1019
]
],
[
[
629,
63,
723
],
[
723,
25,
1019
]
],
[
[
629,
24,
655
],
[
655,
25,
1019
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
]
] | Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Sirolimus may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Sirolimus may lead to a major life threatening interaction when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Deflazacort
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may lead to a major life threatening interaction when taken with Deflazacort |
DB00860 | DB06335 | 891 | 761 | [
"DDInter1513",
"DDInter1646"
] | Prednisolone | Saxagliptin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
891,
24,
761
]
],
[
[
891,
6,
8374
],
[
8374,
45,
761
]
],
[
[
891,
21,
28722
],
[
28722,
60,
761
]
],
[
[
891,
62,
307
],
[
307,
23,
761
]
],
[
[
891,
40,
1103
],
[
1103,
23,
761
]
],
[
[
891,
63,
1577
],
[
1577,
24,
761
]
],
[
[
891,
24,
178
],
[
178,
24,
761
]
],
[
[
891,
40,
1573
],
[
1573,
24,
761
]
],
[
[
891,
24,
1296
],
[
1296,
63,
761
]
],
[
[
891,
23,
455
],
[
455,
24,
761
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
]
] | Prednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Prednisolone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin |
DB00030 | DB00795 | 1,685 | 50 | [
"DDInter934",
"DDInter1725"
] | Insulin human | Sulfasalazine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607] | Moderate | 1 | [
[
[
1685,
24,
50
]
],
[
[
1685,
24,
161
],
[
161,
1,
50
]
],
[
[
1685,
63,
305
],
[
305,
24,
50
]
],
[
[
1685,
24,
959
],
[
959,
63,
50
]
],
[
[
1685,
24,
245
],
[
245,
24,
50
]
],
[
[
1685,
24,
629
],
[
629,
64,
50
]
],
[
[
1685,
24,
161
],
[
161,
1,
11249
],
[
11249,
1,
50
]
],
[
[
1685,
63,
305
],
[
305,
24,
161
],
[
161,
1,
50
]
],
[
[
1685,
24,
959
],
[
959,
24,
712
],
[
712,
1,
50
]
],
[
[
1685,
24,
850
],
[
850,
63,
161
],
[
161,
1,
50
]
]
] | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfaphenazole"
],
[
"Sulfaphenazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
]
]
] | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Sulfasalazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound) |
DB00295 | DB00376 | 475 | 1,105 | [
"DDInter1244",
"DDInter1870"
] | Morphine | Trihexyphenidyl | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa]. Trihexyphenidyl was granted FDA approval on 13 May 1949. | Moderate | 1 | [
[
[
475,
24,
1105
]
],
[
[
475,
24,
456
],
[
456,
1,
1105
]
],
[
[
475,
24,
1386
],
[
1386,
40,
1105
]
],
[
[
475,
21,
28676
],
[
28676,
60,
1105
]
],
[
[
475,
24,
412
],
[
412,
63,
1105
]
],
[
[
475,
24,
1594
],
[
1594,
24,
1105
]
],
[
[
475,
63,
701
],
[
701,
24,
1105
]
],
[
[
475,
24,
1192
],
[
1192,
74,
1105
]
],
[
[
475,
24,
456
],
[
456,
1,
11264
],
[
11264,
40,
1105
]
],
[
[
475,
24,
1386
],
[
1386,
40,
11264
],
[
11264,
40,
1105
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
],
[
"Biperiden",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procyclidine"
],
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
],
[
"Biperiden",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procyclidine"
],
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden and Biperiden (Compound) resembles Trihexyphenidyl (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine and Procyclidine (Compound) resembles Trihexyphenidyl (Compound)
Morphine (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Trihexyphenidyl (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium (Compound) resembles Trihexyphenidyl (Compound) and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Biperiden and Biperiden (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Trihexyphenidyl (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine and Procyclidine (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Trihexyphenidyl (Compound) |
DB12130 | DB12941 | 1,017 | 466 | [
"DDInter1094",
"DDInter481"
] | Lorlatinib | Darolutamide | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Major | 2 | [
[
[
1017,
25,
466
]
],
[
[
1017,
64,
1622
],
[
1622,
23,
466
]
],
[
[
1017,
63,
34
],
[
34,
23,
466
]
],
[
[
1017,
25,
283
],
[
283,
23,
466
]
],
[
[
1017,
24,
971
],
[
971,
23,
466
]
],
[
[
1017,
24,
159
],
[
159,
62,
466
]
],
[
[
1017,
25,
68
],
[
68,
62,
466
]
],
[
[
1017,
63,
738
],
[
738,
24,
466
]
],
[
[
1017,
64,
1040
],
[
1040,
24,
466
]
],
[
[
1017,
25,
733
],
[
733,
63,
466
]
]
] | [
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eslicarbazepine"
],
[
"Eslicarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
]
] | Lorlatinib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lorlatinib may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lorlatinib may lead to a major life threatening interaction when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide |
DB09043 | DB09128 | 135 | 1,241 | [
"DDInter36",
"DDInter231"
] | Albiglutide | Brexpiprazole | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric disorders, such as post-traumatic stress disorder. | Moderate | 1 | [
[
[
135,
24,
1241
]
],
[
[
135,
62,
1647
],
[
1647,
24,
1241
]
],
[
[
135,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
135,
63,
1179
],
[
1179,
24,
1241
]
],
[
[
135,
24,
98
],
[
98,
24,
1241
]
],
[
[
135,
63,
609
],
[
609,
25,
1241
]
],
[
[
135,
62,
1647
],
[
1647,
24,
222
],
[
222,
24,
1241
]
],
[
[
135,
24,
1296
],
[
1296,
63,
549
],
[
549,
24,
1241
]
],
[
[
135,
63,
1179
],
[
1179,
24,
549
],
[
549,
24,
1241
]
],
[
[
135,
62,
467
],
[
467,
23,
549
],
[
549,
24,
1241
]
]
] | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Albiglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
]
] | Albiglutide may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Brexpiprazole
Albiglutide may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Albiglutide may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole |
DB01159 | DB06209 | 419 | 256 | [
"DDInter854",
"DDInter1508"
] | Halothane | Prasugrel | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Minor | 0 | [
[
[
419,
23,
256
]
],
[
[
419,
6,
8374
],
[
8374,
45,
256
]
],
[
[
419,
63,
888
],
[
888,
23,
256
]
],
[
[
419,
63,
475
],
[
475,
24,
256
]
],
[
[
419,
24,
407
],
[
407,
63,
256
]
],
[
[
419,
24,
477
],
[
477,
24,
256
]
],
[
[
419,
25,
39
],
[
39,
64,
256
]
],
[
[
419,
64,
702
],
[
702,
25,
256
]
],
[
[
419,
24,
1213
],
[
1213,
25,
256
]
],
[
[
419,
6,
8374
],
[
8374,
45,
752
],
[
752,
23,
256
]
]
] | [
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
]
] | Halothane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Halothane may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Prasugrel
Halothane may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Prasugrel
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Prasugrel
Halothane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel |
DB00344 | DB08897 | 1,302 | 1,429 | [
"DDInter1543",
"DDInter22"
] | Protriptyline | Aclidinium | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1302,
24,
1429
]
],
[
[
1302,
63,
352
],
[
352,
24,
1429
]
],
[
[
1302,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
1302,
21,
28817
],
[
28817,
60,
1429
]
],
[
[
1302,
24,
1116
],
[
1116,
63,
1429
]
],
[
[
1302,
40,
413
],
[
413,
24,
1429
]
],
[
[
1302,
1,
1405
],
[
1405,
24,
1429
]
],
[
[
1302,
24,
1415
],
[
1415,
35,
1429
]
],
[
[
1302,
63,
352
],
[
352,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
1302,
24,
1511
],
[
1511,
63,
352
],
[
352,
24,
1429
]
]
] | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
],
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
]
] | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Aclidinium (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium and Tiotropium (Compound) resembles Aclidinium (Compound) and Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium |
DB00987 | DB14783 | 1,224 | 287 | [
"DDInter460",
"DDInter574"
] | Cytarabine | Diroximel fumarate | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
1224,
24,
287
]
],
[
[
1224,
64,
1101
],
[
1101,
24,
287
]
],
[
[
1224,
63,
1560
],
[
1560,
24,
287
]
],
[
[
1224,
24,
384
],
[
384,
24,
287
]
],
[
[
1224,
35,
1488
],
[
1488,
24,
287
]
],
[
[
1224,
40,
1426
],
[
1426,
24,
287
]
],
[
[
1224,
74,
372
],
[
372,
24,
287
]
],
[
[
1224,
37,
770
],
[
770,
24,
287
]
],
[
[
1224,
25,
1510
],
[
1510,
25,
287
]
],
[
[
1224,
64,
1066
],
[
1066,
25,
287
]
]
] | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound)",
"Azacitidine"
],
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
]
] | Cytarabine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine (Compound) resembles Fludarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine (Compound) resembles Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine (Compound) resembles Clofarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Cytarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cytarabine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Cytarabine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate |
DB01218 | DB12161 | 1,493 | 730 | [
"DDInter852",
"DDInter512"
] | Halofantrine | Deutetrabenazine | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. | Major | 2 | [
[
[
1493,
25,
730
]
],
[
[
1493,
62,
112
],
[
112,
23,
730
]
],
[
[
1493,
64,
322
],
[
322,
24,
730
]
],
[
[
1493,
63,
1559
],
[
1559,
24,
730
]
],
[
[
1493,
25,
971
],
[
971,
24,
730
]
],
[
[
1493,
24,
286
],
[
286,
24,
730
]
],
[
[
1493,
25,
283
],
[
283,
63,
730
]
],
[
[
1493,
64,
11
],
[
11,
25,
730
]
],
[
[
1493,
25,
877
],
[
877,
64,
730
]
],
[
[
1493,
25,
1487
],
[
1487,
25,
730
]
]
] | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
]
] | Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Deutetrabenazine
Halofantrine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Deutetrabenazine |
DB00911 | DB08870 | 458 | 850 | [
"DDInter1811",
"DDInter228"
] | Tinidazole | Brentuximab vedotin | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
458,
24,
850
]
],
[
[
458,
24,
788
],
[
788,
24,
850
]
],
[
[
458,
63,
896
],
[
896,
24,
850
]
],
[
[
458,
24,
1155
],
[
1155,
63,
850
]
],
[
[
458,
40,
112
],
[
112,
24,
850
]
],
[
[
458,
64,
1091
],
[
1091,
24,
850
]
],
[
[
458,
24,
1510
],
[
1510,
64,
850
]
],
[
[
458,
24,
1377
],
[
1377,
25,
850
]
],
[
[
458,
63,
581
],
[
581,
25,
850
]
],
[
[
458,
24,
788
],
[
788,
40,
671
],
[
671,
24,
850
]
]
] | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
]
] | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tinidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Brentuximab vedotin
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB00468 | DB11110 | 1,424 | 603 | [
"DDInter1557",
"DDInter1115"
] | Quinine | Magnesium citrate | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
1424,
24,
603
]
],
[
[
1424,
25,
57
],
[
57,
24,
603
]
],
[
[
1424,
24,
789
],
[
789,
24,
603
]
],
[
[
1424,
64,
494
],
[
494,
24,
603
]
],
[
[
1424,
24,
484
],
[
484,
63,
603
]
],
[
[
1424,
63,
1100
],
[
1100,
24,
603
]
],
[
[
1424,
25,
1375
],
[
1375,
63,
603
]
],
[
[
1424,
62,
964
],
[
964,
24,
603
]
],
[
[
1424,
23,
1620
],
[
1620,
24,
603
]
],
[
[
1424,
24,
627
],
[
627,
64,
603
]
]
] | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
"Bictegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium citrate"
]
]
] | Quinine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may lead to a major life threatening interaction when taken with Magnesium citrate |
DB00619 | DB00834 | 1,419 | 932 | [
"DDInter909",
"DDInter1215"
] | Imatinib | Mifepristone | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Moderate | 1 | [
[
[
1419,
24,
932
]
],
[
[
1419,
6,
7524
],
[
7524,
45,
932
]
],
[
[
1419,
21,
28762
],
[
28762,
60,
932
]
],
[
[
1419,
62,
1101
],
[
1101,
23,
932
]
],
[
[
1419,
24,
1499
],
[
1499,
63,
932
]
],
[
[
1419,
24,
723
],
[
723,
24,
932
]
],
[
[
1419,
63,
522
],
[
522,
24,
932
]
],
[
[
1419,
35,
1468
],
[
1468,
63,
932
]
],
[
[
1419,
25,
976
],
[
976,
63,
932
]
],
[
[
1419,
24,
51
],
[
51,
25,
932
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
]
]
] | Imatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Imatinib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Imatinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Mifepristone |
DB00065 | DB00694 | 581 | 51 | [
"DDInter923",
"DDInter485"
] | Infliximab | Daunorubicin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Major | 2 | [
[
[
581,
25,
51
]
],
[
[
581,
24,
112
],
[
112,
62,
51
]
],
[
[
581,
24,
1430
],
[
1430,
63,
51
]
],
[
[
581,
25,
1468
],
[
1468,
63,
51
]
],
[
[
581,
25,
134
],
[
134,
24,
51
]
],
[
[
581,
24,
58
],
[
58,
24,
51
]
],
[
[
581,
64,
1648
],
[
1648,
24,
51
]
],
[
[
581,
23,
1461
],
[
1461,
24,
51
]
],
[
[
581,
25,
1624
],
[
1624,
64,
51
]
],
[
[
581,
24,
33
],
[
33,
64,
51
]
]
] | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
]
]
] | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Infliximab may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Daunorubicin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Daunorubicin |
DB00480 | DB12035 | 1,668 | 943 | [
"DDInter1035",
"DDInter1641"
] | Lenalidomide | Sarecycline | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc. | Moderate | 1 | [
[
[
1668,
24,
943
]
],
[
[
1668,
24,
1670
],
[
1670,
24,
943
]
],
[
[
1668,
23,
126
],
[
126,
24,
943
]
],
[
[
1668,
63,
322
],
[
322,
24,
943
]
],
[
[
1668,
24,
1670
],
[
1670,
23,
1135
],
[
1135,
23,
943
]
],
[
[
1668,
24,
850
],
[
850,
24,
1670
],
[
1670,
24,
943
]
],
[
[
1668,
23,
126
],
[
126,
24,
1606
],
[
1606,
24,
943
]
],
[
[
1668,
24,
384
],
[
384,
64,
1135
],
[
1135,
23,
943
]
],
[
[
1668,
63,
322
],
[
322,
63,
1181
],
[
1181,
24,
943
]
],
[
[
1668,
24,
738
],
[
738,
63,
1456
],
[
1456,
24,
943
]
]
] | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
]
] | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline |
DB01396 | DB11093 | 1,482 | 636 | [
"DDInter553",
"DDInter273"
] | Digitoxin | Calcium citrate | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1482,
24,
636
]
],
[
[
1482,
63,
1572
],
[
1572,
24,
636
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
636
]
],
[
[
1482,
23,
115
],
[
115,
25,
636
]
],
[
[
1482,
63,
1572
],
[
1572,
23,
504
],
[
504,
24,
636
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
1572
],
[
1572,
24,
636
]
],
[
[
1482,
63,
964
],
[
964,
1,
1572
],
[
1572,
24,
636
]
],
[
[
1482,
63,
1231
],
[
1231,
63,
1252
],
[
1252,
24,
636
]
],
[
[
1482,
63,
1669
],
[
1669,
40,
1572
],
[
1572,
24,
636
]
],
[
[
1482,
6,
4973
],
[
4973,
45,
819
],
[
819,
24,
636
]
]
] | [
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Digitoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
]
] | Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Digitoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate |
DB00604 | DB13074 | 1,425 | 877 | [
"DDInter385",
"DDInter1110"
] | Cisapride | Macimorelin | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Major | 2 | [
[
[
1425,
25,
877
]
],
[
[
1425,
23,
112
],
[
112,
23,
877
]
],
[
[
1425,
63,
85
],
[
85,
24,
877
]
],
[
[
1425,
24,
673
],
[
673,
24,
877
]
],
[
[
1425,
25,
913
],
[
913,
24,
877
]
],
[
[
1425,
64,
1262
],
[
1262,
24,
877
]
],
[
[
1425,
25,
485
],
[
485,
25,
877
]
],
[
[
1425,
64,
87
],
[
87,
25,
877
]
],
[
[
1425,
24,
144
],
[
144,
25,
877
]
],
[
[
1425,
25,
1399
],
[
1399,
64,
877
]
]
] | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perflutren"
],
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
]
] | Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Cisapride may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Cisapride may lead to a major life threatening interaction when taken with Perflutren and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Cisapride may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Cisapride may lead to a major life threatening interaction when taken with Amoxapine and Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Cisapride may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Macimorelin |
DB00501 | DB01242 | 752 | 1,237 | [
"DDInter380",
"DDInter410"
] | Cimetidine | Clomipramine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
752,
24,
1237
]
],
[
[
752,
25,
684
],
[
684,
1,
1237
]
],
[
[
752,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
752,
63,
902
],
[
902,
40,
1237
]
],
[
[
752,
62,
216
],
[
216,
1,
1237
]
],
[
[
752,
63,
21
],
[
21,
1,
1237
]
],
[
[
752,
24,
1216
],
[
1216,
40,
1237
]
],
[
[
752,
6,
7950
],
[
7950,
45,
1237
]
],
[
[
752,
21,
28882
],
[
28882,
60,
1237
]
],
[
[
752,
23,
112
],
[
112,
23,
1237
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clomipramine"
]
]
] | Cimetidine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Clomipramine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Clomipramine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Clomipramine (Compound)
Cimetidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clomipramine (Compound)
Cimetidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Clomipramine (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clomipramine |
DB00384 | DB09038 | 1,275 | 1,450 | [
"DDInter1859",
"DDInter636"
] | Triamterene | Empagliflozin | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
1275,
24,
1450
]
],
[
[
1275,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1275,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
1275,
24,
1455
],
[
1455,
63,
1450
]
],
[
[
1275,
63,
1061
],
[
1061,
63,
461
],
[
461,
24,
1450
]
],
[
[
1275,
24,
1486
],
[
1486,
63,
461
],
[
461,
24,
1450
]
],
[
[
1275,
24,
870
],
[
870,
1,
1103
],
[
1103,
23,
1450
]
],
[
[
1275,
24,
891
],
[
891,
40,
1103
],
[
1103,
23,
1450
]
],
[
[
1275,
1,
706
],
[
706,
24,
1142
],
[
1142,
24,
1450
]
],
[
[
1275,
63,
999
],
[
999,
24,
461
],
[
461,
24,
1450
]
]
] | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} (Compound) resembles {v} (Compound)",
"Lamotrigine"
],
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
]
] | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Triamterene (Compound) resembles Lamotrigine (Compound) and Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin |
DB00747 | DB01242 | 1,442 | 1,237 | [
"DDInter1647",
"DDInter410"
] | Scopolamine | Clomipramine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423, | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
1442,
24,
1237
]
],
[
[
1442,
63,
684
],
[
684,
1,
1237
]
],
[
[
1442,
24,
272
],
[
272,
24,
1237
]
],
[
[
1442,
24,
146
],
[
146,
40,
1237
]
],
[
[
1442,
24,
1630
],
[
1630,
1,
1237
]
],
[
[
1442,
24,
820
],
[
820,
63,
1237
]
],
[
[
1442,
6,
4973
],
[
4973,
45,
1237
]
],
[
[
1442,
21,
28703
],
[
28703,
60,
1237
]
],
[
[
1442,
74,
85
],
[
85,
24,
1237
]
],
[
[
1442,
63,
701
],
[
701,
24,
1237
]
]
] | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
]
] | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Clomipramine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Clomipramine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Scopolamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clomipramine (Compound)
Scopolamine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Clomipramine (Compound)
Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine |
DB00367 | DB01024 | 566 | 1,096 | [
"DDInter1061",
"DDInter1252"
] | Levonorgestrel | Mycophenolic acid | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.[A181991,L7760,L7778] Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogen | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection. | Major | 2 | [
[
[
566,
25,
1096
]
],
[
[
566,
18,
5930
],
[
5930,
45,
1096
]
],
[
[
566,
7,
18134
],
[
18134,
46,
1096
]
],
[
[
566,
18,
2389
],
[
2389,
46,
1096
]
],
[
[
566,
18,
4046
],
[
4046,
57,
1096
]
],
[
[
566,
7,
5178
],
[
5178,
57,
1096
]
],
[
[
566,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
566,
63,
1031
],
[
1031,
23,
1096
]
],
[
[
566,
24,
609
],
[
609,
63,
1096
]
],
[
[
566,
24,
629
],
[
629,
24,
1096
]
]
] | [
[
[
"Levonorgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) downregulates {v} (Gene)",
"IMPDH2"
],
[
"IMPDH2",
"{u} (Gene) is bound by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC85B"
],
[
"CCDC85B",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) downregulates {v} (Gene)",
"PIK3C2B"
],
[
"PIK3C2B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) upregulates {v} (Gene)",
"XBP1"
],
[
"XBP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
]
] | Levonorgestrel (Compound) downregulates IMPDH2 (Gene) and IMPDH2 (Gene) is bound by Mycophenolic acid (Compound)
Levonorgestrel (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Mycophenolic acid (Compound)
Levonorgestrel (Compound) downregulates CCDC85B (Gene) and CCDC85B (Gene) is upregulated by Mycophenolic acid (Compound)
Levonorgestrel (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is downregulated by Mycophenolic acid (Compound)
Levonorgestrel (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Mycophenolic acid (Compound)
Levonorgestrel (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid |
DB00916 | DB05812 | 112 | 1,374 | [
"DDInter1202",
"DDInter8"
] | Metronidazole | Abiraterone | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Minor | 0 | [
[
[
112,
23,
1374
]
],
[
[
112,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
112,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
112,
23,
1247
],
[
1247,
23,
1374
]
],
[
[
112,
64,
1091
],
[
1091,
23,
1374
]
],
[
[
112,
63,
479
],
[
479,
23,
1374
]
],
[
[
112,
63,
1028
],
[
1028,
24,
1374
]
],
[
[
112,
24,
1399
],
[
1399,
63,
1374
]
],
[
[
112,
62,
1302
],
[
1302,
24,
1374
]
],
[
[
112,
23,
495
],
[
495,
24,
1374
]
]
] | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
]
] | Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Metronidazole (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Metronidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Protriptyline and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ezogabine and Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone |
DB01166 | DB04865 | 477 | 4 | [
"DDInter379",
"DDInter1335"
] | Cilostazol | Omacetaxine mepesuccinate | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Major | 2 | [
[
[
477,
25,
4
]
],
[
[
477,
7,
4450
],
[
4450,
46,
4
]
],
[
[
477,
18,
16896
],
[
16896,
57,
4
]
],
[
[
477,
63,
770
],
[
770,
24,
4
]
],
[
[
477,
25,
1250
],
[
1250,
63,
4
]
],
[
[
477,
24,
1616
],
[
1616,
63,
4
]
],
[
[
477,
64,
11
],
[
11,
24,
4
]
],
[
[
477,
24,
77
],
[
77,
24,
4
]
],
[
[
477,
25,
1213
],
[
1213,
24,
4
]
],
[
[
477,
63,
831
],
[
831,
25,
4
]
]
] | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} (Compound) upregulates {v} (Gene)",
"RRP8"
],
[
"RRP8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} (Compound) downregulates {v} (Gene)",
"IARS2"
],
[
"IARS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Cilostazol (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Cilostazol (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate |
DB00682 | DB01044 | 126 | 246 | [
"DDInter1951",
"DDInter809"
] | Warfarin | Gatifloxacin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Major | 2 | [
[
[
126,
25,
246
]
],
[
[
126,
25,
739
],
[
739,
1,
246
]
],
[
[
126,
64,
1176
],
[
1176,
1,
246
]
],
[
[
126,
25,
945
],
[
945,
40,
246
]
],
[
[
126,
64,
1467
],
[
1467,
40,
246
]
],
[
[
126,
6,
1829
],
[
1829,
45,
246
]
],
[
[
126,
23,
1053
],
[
1053,
62,
246
]
],
[
[
126,
25,
60
],
[
60,
62,
246
]
],
[
[
126,
24,
328
],
[
328,
23,
246
]
],
[
[
126,
24,
1532
],
[
1532,
62,
246
]
]
] | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
]
] | Warfarin may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Warfarin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Warfarin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Compound)
Warfarin may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Gatifloxacin (Compound)
Warfarin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Gatifloxacin (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Warfarin may lead to a major life threatening interaction when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin |
DB00443 | DB00705 | 251 | 441 | [
"DDInter195",
"DDInter496"
] | Betamethasone | Delavirdine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
251,
24,
441
]
],
[
[
251,
6,
8374
],
[
8374,
45,
441
]
],
[
[
251,
21,
28709
],
[
28709,
60,
441
]
],
[
[
251,
1,
1220
],
[
1220,
63,
441
]
],
[
[
251,
24,
609
],
[
609,
63,
441
]
],
[
[
251,
23,
1283
],
[
1283,
63,
441
]
],
[
[
251,
1,
1351
],
[
1351,
24,
441
]
],
[
[
251,
63,
1101
],
[
1101,
24,
441
]
],
[
[
251,
24,
126
],
[
126,
24,
441
]
],
[
[
251,
40,
870
],
[
870,
24,
441
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
]
] | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Delavirdine (Compound)
Betamethasone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine |
DB00736 | DB09263 | 660 | 1,436 | [
"DDInter676",
"DDInter1399"
] | Esomeprazole | Patiromer | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including,, and, for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including,,,, and. Esomeprazole is the s-isomer of, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as, without any significant differences between the two compounds _in vitro_. Esome | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. | Moderate | 1 | [
[
[
660,
24,
1436
]
],
[
[
660,
24,
428
],
[
428,
63,
1436
]
],
[
[
660,
40,
837
],
[
837,
24,
1436
]
],
[
[
660,
63,
1152
],
[
1152,
24,
1436
]
],
[
[
660,
1,
1215
],
[
1215,
24,
1436
]
],
[
[
660,
24,
1596
],
[
1596,
24,
1436
]
],
[
[
660,
24,
428
],
[
428,
63,
101
],
[
101,
24,
1436
]
],
[
[
660,
40,
837
],
[
837,
24,
428
],
[
428,
63,
1436
]
],
[
[
660,
63,
1152
],
[
1152,
24,
841
],
[
841,
63,
1436
]
],
[
[
660,
1,
1215
],
[
1215,
24,
428
],
[
428,
63,
1436
]
]
] | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
],
[
"Calcium glubionate anhydrous",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
]
] | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous and Calcium glubionate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer |
DB06674 | DB11834 | 908 | 1,303 | [
"DDInter837",
"DDInter849"
] | Golimumab | Guselkumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. | Major | 2 | [
[
[
908,
25,
1303
]
],
[
[
908,
23,
1193
],
[
1193,
23,
1303
]
],
[
[
908,
62,
1461
],
[
1461,
23,
1303
]
],
[
[
908,
63,
792
],
[
792,
24,
1303
]
],
[
[
908,
24,
949
],
[
949,
24,
1303
]
],
[
[
908,
25,
713
],
[
713,
24,
1303
]
],
[
[
908,
64,
147
],
[
147,
24,
1303
]
],
[
[
908,
25,
287
],
[
287,
63,
1303
]
],
[
[
908,
24,
987
],
[
987,
63,
1303
]
],
[
[
908,
25,
375
],
[
375,
25,
1303
]
]
] | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
]
] | Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Golimumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Guselkumab |
DB00242 | DB08870 | 1,064 | 850 | [
"DDInter392",
"DDInter228"
] | Cladribine | Brentuximab vedotin | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Major | 2 | [
[
[
1064,
25,
850
]
],
[
[
1064,
24,
496
],
[
496,
63,
850
]
],
[
[
1064,
25,
611
],
[
611,
24,
850
]
],
[
[
1064,
25,
1583
],
[
1583,
63,
850
]
],
[
[
1064,
35,
1477
],
[
1477,
24,
850
]
],
[
[
1064,
64,
367
],
[
367,
24,
850
]
],
[
[
1064,
24,
171
],
[
171,
24,
850
]
],
[
[
1064,
37,
1224
],
[
1224,
24,
850
]
],
[
[
1064,
63,
912
],
[
912,
24,
850
]
],
[
[
1064,
36,
1488
],
[
1488,
24,
850
]
]
] | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
]
] | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine (Compound) resembles Telbivudine (Compound) and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib and Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cladribine may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Cladribine (Compound) resembles Fludarabine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB00812 | DB01229 | 998 | 973 | [
"DDInter1451",
"DDInter1377"
] | Phenylbutazone | Paclitaxel | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822) | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Moderate | 1 | [
[
[
998,
24,
973
]
],
[
[
998,
24,
310
],
[
310,
63,
973
]
],
[
[
998,
6,
8374
],
[
8374,
45,
973
]
],
[
[
998,
40,
307
],
[
307,
23,
973
]
],
[
[
998,
40,
362
],
[
362,
24,
973
]
],
[
[
998,
63,
1555
],
[
1555,
24,
973
]
],
[
[
998,
25,
1213
],
[
1213,
63,
973
]
],
[
[
998,
1,
804
],
[
804,
24,
973
]
],
[
[
998,
62,
168
],
[
168,
24,
973
]
],
[
[
998,
25,
629
],
[
629,
24,
973
]
]
] | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfinpyrazone"
],
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Phenylbutazone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Phenylbutazone (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Phenylbutazone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB09330 | DB11652 | 985 | 1,155 | [
"DDInter1352",
"DDInter1891"
] | Osimertinib | Tucatinib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Major | 2 | [
[
[
985,
25,
1155
]
],
[
[
985,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
985,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
985,
63,
659
],
[
659,
24,
1155
]
],
[
[
985,
24,
466
],
[
466,
63,
1155
]
],
[
[
985,
62,
168
],
[
168,
24,
1155
]
],
[
[
985,
25,
982
],
[
982,
63,
1155
]
],
[
[
985,
25,
351
],
[
351,
64,
1155
]
],
[
[
985,
63,
1362
],
[
1362,
25,
1155
]
],
[
[
985,
64,
1510
],
[
1510,
25,
1155
]
]
] | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
]
] | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Osimertinib may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Osimertinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Osimertinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Osimertinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Tucatinib |
DB00445 | DB05294 | 322 | 1,069 | [
"DDInter655",
"DDInter1917"
] | Epirubicin | Vandetanib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
322,
25,
1069
]
],
[
[
322,
24,
1195
],
[
1195,
40,
1069
]
],
[
[
322,
63,
883
],
[
883,
40,
1069
]
],
[
[
322,
5,
11648
],
[
11648,
44,
1069
]
],
[
[
322,
6,
10417
],
[
10417,
45,
1069
]
],
[
[
322,
18,
9202
],
[
9202,
45,
1069
]
],
[
[
322,
7,
10365
],
[
10365,
45,
1069
]
],
[
[
322,
21,
29343
],
[
29343,
60,
1069
]
],
[
[
322,
23,
1247
],
[
1247,
23,
1069
]
],
[
[
322,
24,
659
],
[
659,
63,
1069
]
]
] | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} (Compound) treats {v} (Disease)",
"thyroid cancer"
],
[
"thyroid cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"PLK4"
],
[
"PLK4",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"STK10"
],
[
"STK10",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Blood creatinine increased"
],
[
"Blood creatinine increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
]
] | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Vandetanib (Compound)
Epirubicin (Compound) treats thyroid cancer (Disease) and thyroid cancer (Disease) is treated by Vandetanib (Compound)
Epirubicin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Vandetanib (Compound)
Epirubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Vandetanib (Compound)
Epirubicin (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Vandetanib (Compound)
Epirubicin (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib |
DB00530 | DB01129 | 1,195 | 379 | [
"DDInter667",
"DDInter1559"
] | Erlotinib | Rabeprazole | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Major | 2 | [
[
[
1195,
25,
379
]
],
[
[
1195,
64,
1215
],
[
1215,
40,
379
]
],
[
[
1195,
25,
660
],
[
660,
1,
379
]
],
[
[
1195,
64,
837
],
[
837,
1,
379
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
379
]
],
[
[
1195,
21,
28948
],
[
28948,
60,
379
]
],
[
[
1195,
24,
1468
],
[
1468,
62,
379
]
],
[
[
1195,
40,
1069
],
[
1069,
62,
379
]
],
[
[
1195,
24,
947
],
[
947,
63,
379
]
],
[
[
1195,
63,
215
],
[
215,
24,
379
]
]
] | [
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Interstitial pneumonia"
],
[
"Interstitial pneumonia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
],
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
]
] | Erlotinib may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Erlotinib may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Compound)
Erlotinib may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazole (Compound) resembles Rabeprazole (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rabeprazole (Compound)
Erlotinib (Compound) causes Interstitial pneumonia (Side Effect) and Interstitial pneumonia (Side Effect) is caused by Rabeprazole (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Rabeprazole
Erlotinib (Compound) resembles Vandetanib (Compound) and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Rabeprazole
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Riociguat and Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole |
DB01206 | DB08886 | 37 | 637 | [
"DDInter1086",
"DDInter126"
] | Lomustine | Asparaginase Erwinia chrysanthemi | An alkylating agent of value against both hematologic malignancies and solid tumors. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
37,
24,
637
]
],
[
[
37,
63,
328
],
[
328,
24,
637
]
],
[
[
37,
24,
850
],
[
850,
24,
637
]
],
[
[
37,
24,
1613
],
[
1613,
63,
637
]
],
[
[
37,
64,
581
],
[
581,
24,
637
]
],
[
[
37,
74,
552
],
[
552,
24,
637
]
],
[
[
37,
25,
1510
],
[
1510,
25,
637
]
],
[
[
37,
64,
1377
],
[
1377,
25,
637
]
],
[
[
37,
63,
328
],
[
328,
63,
1686
],
[
1686,
24,
637
]
],
[
[
37,
63,
1686
],
[
1686,
24,
328
],
[
328,
24,
637
]
]
] | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Lomustine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00586 | DB00594 | 1,512 | 863 | [
"DDInter537",
"DDInter68"
] | Diclofenac | Amiloride | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | Moderate | 1 | [
[
[
1512,
24,
863
]
],
[
[
1512,
6,
5538
],
[
5538,
45,
863
]
],
[
[
1512,
21,
29434
],
[
29434,
60,
863
]
],
[
[
1512,
62,
752
],
[
752,
23,
863
]
],
[
[
1512,
25,
707
],
[
707,
63,
863
]
],
[
[
1512,
63,
1061
],
[
1061,
24,
863
]
],
[
[
1512,
24,
617
],
[
617,
63,
863
]
],
[
[
1512,
24,
1621
],
[
1621,
64,
863
]
],
[
[
1512,
6,
5538
],
[
5538,
39,
6877
],
[
6877,
45,
863
]
],
[
[
1512,
21,
29434
],
[
29434,
60,
549
],
[
549,
63,
863
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ASIC1"
],
[
"ASIC1",
"{u} (Gene) is bound by {v} (Compound)",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ASIC1"
],
[
"ASIC1",
"{u} (Gene) interacts with {v} (Gene)",
"ASIC2"
],
[
"ASIC2",
"{u} (Gene) is bound by {v} (Compound)",
"Amiloride"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
]
] | Diclofenac (Compound) binds ASIC1 (Gene) and ASIC1 (Gene) is bound by Amiloride (Compound)
Diclofenac (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Amiloride (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Amiloride
Diclofenac may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Amiloride
Diclofenac (Compound) binds ASIC1 (Gene) and ASIC1 (Gene) interacts with ASIC2 (Gene) and ASIC2 (Gene) is bound by Amiloride (Compound)
Diclofenac (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride |
DB00307 | DB09389 | 1,101 | 517 | [
"DDInter202",
"DDInter1315"
] | Bexarotene | Norgestrel | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Major | 2 | [
[
[
1101,
25,
517
]
],
[
[
1101,
24,
1130
],
[
1130,
23,
517
]
],
[
[
1101,
25,
52
],
[
52,
24,
517
]
],
[
[
1101,
24,
159
],
[
159,
63,
517
]
],
[
[
1101,
23,
86
],
[
86,
24,
517
]
],
[
[
1101,
64,
581
],
[
581,
24,
517
]
],
[
[
1101,
24,
1254
],
[
1254,
24,
517
]
],
[
[
1101,
62,
600
],
[
600,
24,
517
]
],
[
[
1101,
23,
1017
],
[
1017,
63,
517
]
],
[
[
1101,
63,
58
],
[
58,
24,
517
]
]
] | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
]
] | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Bexarotene may lead to a major life threatening interaction when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.